



phamax

January 2015



HEALTHCARE
MARKET ACCESS
MOROCCO



phamax



TABLE OF CONTENTS

1 EXECUTIVE SUMMARY	5
2 COUNTRY LANDSCAPE.....	7
2.1 Geography	7
2.2 Economic environment.....	8
2.3 Demographics.....	10
2.4 Political structure and environment.....	13
3 HEALTHCARE INFRASTRUCTURE.....	14
3.1.1 Healthcare system.....	16
4 MARKET ACCESS.....	20
4.1 Health insurance system	20
4.1.1 AMO: Mandatory health insurance (<i>Assurance Maladie Obligatoire</i>).....	21
4.1.2 RAMED: Medical assistance scheme (<i>Régime d'Assistance Médicale</i>).....	24
4.1.3 INAYA: Health insurance for the self-employed.....	25
4.2 Drug prescribing and dispensing practices	27
4.3 Comparison of regional regulatory agencies and environment	28
4.3.1 Southern African Development Community (SADC):.....	30
4.3.2 Economic Community of West African States (ECOWAS):.....	30
4.3.3 East African Community (EAC):	30
4.4 Drug approval and reimbursement process in Morocco.....	31
5 CONCLUSION	33
6 APPENDIX.....	34
6.1 Glossary.....	34
6.2 Coverage rates for long-term and costly conditions	36
6.3 Essential drug list of Morocco.....	40
6.4 Reimbursement of anti-cancer drugs (in MAD).....	68
6.5 Bibliography	83
6.6 Methodology.....	84
6.6.1 Secondary research.....	84
6.6.2 Data validation.....	84
6.7 Disclaimer.....	84
6.8 Contact us.....	85



LIST OF TABLES

Table 1: GDP Real growth rate of Morocco.....	8
Table 2: GDP composition (2012 estimates) by sector of origin	8
Table 3: Demographic breakdown of Morocco based on 2014 estimates.....	11
Table 4: Major urban cities and their population based on 2011 estimates.....	11
Table 5: Educational parameters	12
Table 6: Access to safe drinking water and sanitation	14
Table 7: Healthcare indicators of Morocco	16
Table 8: Breakdown of healthcare delivery in public and private sectors.....	17
Table 9: Breakdown of income and major expenditure of CNSS and CNOPS for 2012.....	24
Table 10: Breakdown of income and major expenditure of RAMED for 2012	25
Table 11: Coverage rates for long-term and costly conditions.....	36
Table 12: Coverage rate of lasting and costly disorders.....	39
Table 13: Essential drug list of Morocco.....	40
Table 14: Reimbursements of anti-cancer drugs	68



LIST OF FIGURES

Figure 1: Changing trends of demographics of Morocco	10
Figure 2: Breakdown share of hospital beds (A) in public and private hospitals	18
Figure 3: Health care professionals (B) in public and private hospitals	18
Figure 4: Financing of total health expenditure in Morocco	19
Figure 5: Intended coverage of population by insurance scheme	20
Figure 6: Share of AMO coverage by insurance provider	21
Figure 7: CNSS pay-outs for short-term, long-term, and family care (A)	23
Figure 8: CNSS beneficiaries receiving short-term, long-term, and family care (B)	23
Figure 9: Drug approval and reimbursement process in Morocco	32



1 Executive Summary

The Kingdom of Morocco is a country in the *Maghreb* region of North Africa. Morocco obtained independence from French rule on 2nd March, 1956. The country has a constitutional monarchy and an elected parliament. The majority of the country's population belongs to the economically productive age group of 25–54 years, with the median age of the population being 28.1 years. Nearly 57% of population resides in urban locations. Morocco has capitalized on its proximity to Europe and on its relatively cheap labor force to forge an open market oriented economy. As per 2013 estimates, the national GDP (PPP) stands at USD 180 billion, with an estimated per capita income (PPP) of USD 5,500 and an estimated GDP real growth rate of 5.1%. The majority of GDP comes from services sector and mining. However, agriculture employs a huge work force (40%) while contributing 15% to national GDP. However, the income/wealth distribution has a huge gap with Gini coefficient of 0.41.

In terms of its healthcare infrastructure, however, circumstances are not ideal: As per the reports from US government, Morocco has insufficient trained physicians (0.62 per 1,000 people) and hospital beds (1.1 per 1,000 people) for its population. The prevalence of HIV/AIDS in Morocco is comparatively low 0.1% (2012 estimates), indicating the ability of Moroccan MoH in implementing healthcare programs. Over the recent years the data shows that Morocco has achieved significant success in improving maternal and child health. However, for poorer sections of the society access to care is still a problem.

The Ministry of Health (MoH), Government of Morocco and the National Health Insurance Agency (ANAM) are the prime regulatory bodies responsible for overall healthcare access and regulations in Morocco. The MoH is responsible for development and implementation of government policy on public health; the Department of Pharmacy of MoH licenses marketing of new drugs in the country based on safety and efficacy data; and ANAM is the main regulatory body governing health insurance schemes in Morocco. Currently, there are two major health insurance schemes in Morocco: AMO (*Assurance Maladie Obligatoire*) for the salaried public and private sector employees and for self-employed people, and RAMED (*Régime d'Assistance Médicale*) for the poorer sections of society. Both schemes together cover the healthcare needs of more than 50% of the Moroccan population. Being premium based, AMO insurance provides better health coverage than that of the government funded RAMED insurance scheme. The analysis of the spending under both AMO and RAMED indicates that chronic diseases, though accounting for fewer cases still command the majority of expenses.

Public healthcare systems account for the majority of healthcare services (nearly 75% of healthcare in Morocco based on HCPs employed) provided in the country; while the private and non-governmental organization (NGOs) based healthcare systems account for the remaining (~25%). Although public hospitals represent a higher share in terms of number of beds, they receive hardly 10% of insurance spending. This indicates that majority of the patients prefer to attend private



medical hospitals. As per the World Health Organization (WHO), total healthcare expenditure in Morocco amounts to approximately MAD 19 billion (approximately 5% of GDP), of which 51.6% is financed by households independently and 44.4% by collective financing (taxes, insurance, and local authorities).

Approval from Dept. of pharmacy, MoH is necessary before marketing any drug in Morocco. If the drug is already approved by one of the Western regulatory agencies (US FDA or EU EMEA), then the approval process for Morocco would be greatly accelerated. For reimbursement decisions, ANAM assesses new drugs based on their safety and efficacy parameters and also based on their cost implications.

The physicians generally prescribe the drugs that are reimbursed. However, they do have the liberty to prescribe non-reimbursed drugs, in which case the patient will have to pay for themselves.



2 Country landscape

2.1 Geography

Morocco, also known as the Kingdom of Morocco, is a country in the *Maghreb* region of North Africa. The country borders the North Atlantic to the northwest, Algeria to the east, and Mauritania to the south. The political capital of Morocco is Rabat; however, Casablanca is the largest city in the nation. Other major cities are Marrakesh, Tangier, Tetouan, Salé, Fes, Agadir, Meknes, Oujda, Kenitra, and Nador. Morocco is divided into 16 regions, which, in turn, are subdivided into 62 prefectures and provinces. [1].



2.2 Economic environment

Morocco has a liberal economy. Its proximity to Europe and relatively low labor costs compared to that of Europe has helped the country to build a diverse, open-market-oriented regime. As per 2013 estimates, the national GDP (adjusted for purchasing power parity, PPP) stands at USD 180 billion, with an estimated per capita income (PPP) of USD 5,500 and an estimated GDP growth rate (real growth rate) of 5.1% (Table 1) [1].

Table 1: GDP Real growth rate of Morocco

Year	Real growth rate
2013	5.1%
2012	2.7%
2011	5%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

The majority of the Moroccan gross domestic product (GDP) comes from the services sector (Table 2), followed by industries such as mining and processing (especially phosphates), food processing, leather goods, textiles, construction, energy and tourism. However, Morocco still depends heavily on agriculture: it accounts for ~14% of GDP and employs 40%–45% of population. Due to over dependence on agriculture, economic growth has been erratic and relatively slow (Table 2), depending on the variations in rainfall [1].

Table 2: GDP composition (2012 estimates) by sector of origin

Sector	Contribution	Labor share
Agriculture	15.1%	44.6%
Industry	31.7%	19.8%
Services	53.2%	35.5%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Inequality, poverty and vulnerability remain important challenges. Morocco’s Gini coefficient (measure of inequality of income distribution among citizens: coefficient of zero means maximum equality while coefficient of 1 or 100% means maximum inequality) of 0.41 reflects high level of inequality in incomes and access to services. With 13.3% of the population still living just above the poverty



line, it also means that a fifth of Morocco's population (6.3 million people) still lives either in poverty or just above the poverty line. This highlights disproportionate income distribution with low ability to spend for goods and services. Being a country which is largely dependent on the performance of the agricultural sector, the rural populations make up two-thirds of the poor, largely employed in agricultural and informal (including fisheries and forestry) activities. In addition, overall unemployment remains high at around 9%, with urban youth unemployment reaching 35.4%, and labor participation rates among the lowest among emerging economies, with less than half of the population economically active [2]. The United Nations Development Programme (UNDP)'s human development report (HDR) places the human development index (HDI) of Morocco at 0.591, positioning the country at 130 out of 187 countries and territories [3].




2.3 Demographics

The 2014 estimated population of Morocco is about 32.98 million, with a growth rate of 1.02% [1, 2] A majority of this population belongs to the economically productive age group of 25–54 years (Table 3) [1]. The median age of the population is 28.1 years [1]. The birth rate of population is 18.47 births/1,000 population, while the death rate is 4.79 deaths/1,000 population [1]. As per 2011 estimates, 57% of the population lived in urban localities in the country’s major cities with annual rate of urbanization at 1.62%. The major urban cities with their population are mentioned in the Table 4 [1].

As for the age structure, the population under 14 years represented 44.4% in 1960 which changed to 31% in 2004 and will decline to 20.9% in 2030. The population of 15-59 years increased from 51.6% in 1960 to 60% in 2004 and will reach 63.8% in 2030. The population of 60 and over, which was only 4% in 1960 reached to 8% in 2004 and will be representing 15.3% in 2030 [4]. In 2030, there will be a reversal of the age pyramid with a decline in the proportion of young people (under 15 years, who would decrease from 44.4% to 29.8%) and an increase in the proportion of older people from 7% to 15% in 2030 [4].

With the median age group of 28.1 years a majority (42%) of Moroccan population belong to the economically productive age group of 25-54 years. This exemplifies the economic potential of Morocco in terms of business opportunities in various sectors.



The changing trends of demographics in Morocco indicates that the proportion of population which would be economically productive would continue to increase for next 15 years, which in turn would probably translate into better economic prospects for society and increased business opportunities. Furthermore, the increasing percentage of population over the age of 60 years, heralds the diseases and conditions which mainly afflict late age. It also highlights the need for setting up infrastructure to cater for the healthcare needs of elderly.

Morocco's official languages are Arabic and Berber. The country's distinctive group of Moroccan Arabic dialects is referred to as Darija. Approximately 89.8%



of the whole population can communicate to some degree in Moroccan Arabic. While, Arabic is the official language of Morocco, French is generally used in Government, diplomacy, and in business [1].

Table 3: Demographic breakdown of Morocco based on 2014 estimates

Age group (years)	Percentage of population (%)	Male	Female
0–14	26.7%	4,479,676	4,342,605
15–24	17.7%	2,899,041	2,931,856
25–54	42.0%	6,693,877	7,146,696
55–64	7.3%	1,200,733	1,203,447
65 and above	6.3%	940,291	1,148,984

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Table 4: Major urban cities and their population based on 2011 estimates

City name	Estimated population
Casablanca	3.046 million
Rabat	1.843 million
Fes	1.088 million
Marrakech	939,000
Tangier	810,000
Agadir	805,000

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Education in Morocco is free and compulsory through primary school. As per 2011 estimates the literacy rate among 15 years and above who can read and write was 67.1% (male: 76.1%; female: 57.6%). The average school attendance is 11 years (male: 12 years; female: 11 years). The unemployment rate among youth of ages 15 to 24 years is 18.6% (male: 18.4%; female: 19.2%) (Table 5) [1].



Table 5: Educational parameters

Parameter	Rate	Male	Female
Literacy rate (15 years and above)	67.1%	76.1%	57.6%
School attendance (years)	11 years	12 years	11 years
Unemployment rate (15 to 24 years)	18.6%	18.4%	19.2%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Morocco has several universities, institutes for higher learning, and polytechnics. The leading institutions in Morocco include Mohammed V University in Rabat (the country's largest university, with branches in Casablanca and Fès), the Hassan II Agriculture and Veterinary Institute in Rabat (conducts social science research and agricultural research), and Al-Akhawayn University in Ifrane (the first English-language university in North Africa, inaugurated in 1995) [1]. The al-Qarawiyyin University, founded in the city of Fez in 859 AD as a madrasa, is considered by some sources, including UNESCO, to be the oldest active university of the world. As per 2009 data Morocco spends 5.4% of its GDP on education which points towards the availability of relatively skilled resources which can fuel the country's economy.



2.4 Political structure and environment

Morocco obtained independence from French rule on 2nd March 1956. Morocco has a constitutional monarchy and an elected parliament. The King of Morocco holds executive and legislative powers, over the military, foreign affairs, and religious matters. However, executive power is mainly exercised by the elected government, while legislative power is vested in both the government and the two chambers of parliament, the *Assembly of Representatives* and the *Assembly of Councilors* [5]. Morocco has an independent judiciary: the Supreme Court or Court of Cassation which consists of 5-judge panels organized into civil, family matters, commercial, administrative, social, and criminal sections. The Supreme Court judges are appointed by the monarch based on the recommendations of the Supreme Council of the Judiciary. The subordinate courts include courts of appeal; regional and sadad courts (for religious, civil and administrative, and penal adjudication) (2).

Morocco has been given the status of non-NATO ally by the US government. Morocco is included in the European Union's European Neighborhood Policy which aims at bringing the European Union (EU) and its neighbors closer.



3 Healthcare infrastructure

As per the reports from US government, Morocco has insufficient trained physicians (0.62 per 1,000 people) and hospital beds (1.1 per 1,000 people) for its population [1]. Access to safe drinking water and improved sanitation facilities are still poor especially in rural areas (Table 6).

Table 6: Access to safe drinking water and sanitation

Parameter	Urban	Rural	Total
Drinking water (Improved)	98.5%	63.6%	83.6%
Drinking water (Unimproved)	1.5%	36.4%	16.4%
Sanitation (Improved)	84.5%	63.1%	75.4%
Sanitation (Unimproved)	15.5%	36.9%	24.6%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Improved drinking water: piped water into dwelling, yard, or plot; public tap or standpipe; tubewell or borehole; protected dug well; protected spring; or rainwater collection.

Improved sanitation: use of any of the following facilities: flush or pour-flush to a piped sewer system, septic tank or pit latrine; ventilated improved pit (VIP) latrine; pit latrine with slab; or a composting toilet.

Unimproved drinking water: unprotected dug well; unprotected spring; cart with small tank or drum; tanker truck; surface water, which includes rivers, dams, lakes, ponds, streams, canals or irrigation channels; or bottled water.

Unimproved sanitation: use of any of the following facilities: flush or pour-flush not piped to a sewer system, septic tank or pit latrine; pit latrine without a slab or open pit; bucket; hanging toilet or hanging latrine; shared facilities of any type; no facilities; or bush or field.

The prevalence of HIV/AIDS in Morocco is comparatively low 0.1% (2012 estimates) [1], indicating the successful of implementation of AIDS prevention programs. The contraceptive usage rate is nearly 67%. Over recent years the coverage of prenatal care has improved significantly; the proportion of women who had at least one pre-natal consultation has increased from 67.8% in 2004 (85% in urban areas and 48% in rural areas) to 80% in 2010 (94% urban and 68% rural), and the proportion of births attended by skilled personnel has increased from 63% in 2004 to 77.1% in 2011 [4]. These data points showcase the success

The healthcare situation in Morocco is poor; with over 0.62 physicians per 1,000 population, Morocco has far less number of physicians than the WHO prescribed standard of 2.3.



achieved in improving maternal and child healthcare both in terms of improvement of infrastructure and health access.

However, for poorer sections of the society, access to care is still a problem. In Morocco, most of the urban population lives less than 5 km from a healthcare facility, whereas in rural areas, only 30% of the population are less than 5 km from a healthcare facility, 59% live between 5 and 10 km, and 11% live more than 8 km (MoH 2010) [6].

As per 1992 study on the morbidity burden, Morocco faces a triple health challenge: infectious diseases (including maternal and child health) 33.4%; non-communicable diseases 55.8% and trauma 10.8% [4]. The country also faces problems of malnutrition (3.1% children below 5 years as per 2011 estimates) and adult obesity (16.4% as per 2008 estimates) [1]. According to National Population and Family Health survey in 2011, the proportion of children who suffer from, underweight, acute malnutrition and chronic malnutrition are respectively is 3.1%, 2.3% and 14.9% [4]. Tuberculosis, leishmaniasis, community bacterial meningitis and zoonosis still remain major public health problems [4]. According to WHO, as per 2011 data, the burden of disease attributable to environmental degradation in Morocco is 18% of the total disease burden, which is equivalent to 30 DALYs (Adjusted Life Years by disability) lost to 1000 population per year, and 32,000 premature deaths per year [4]. All these above factors indicate the current health burden of Morocco, the possible focus of healthcare reforms and opportunities for private enterprises. Some of the healthcare indicators of Morocco are mentioned in Table 7.



Table 7: Healthcare indicators of Morocco

Parameter	Data
Mean age of mothers at 1 st birth	25.4
Total fertility rate	2.15 children born/woman
Life expectancy at birth	76.51
Maternal mortality rate	100 deaths/100,000 live births
Infant mortality rate	24.52 deaths/1,000 live births
Contraceptive prevalence rate	67.4%
Healthcare expenditure (2011 est)	6% of GDP
Physician density (2009 est)	0.62 physicians per 1,000 population
Hospital bed density (2009 est)	1.1 beds per 1,000 population
Inhabitant per public sector doctor	2,900
Inhabitant per private sector doctor	3,693
Inhabitant per hospital bed (public sector)	1,150
The main causes of mortality reported in 2007	<ul style="list-style-type: none"> • Illnesses of the circulatory system: 22.14% • Tumours: 11.04% • Certain illnesses linked to the perinatal period: 8.84% • Endocrine, nutritional and metabolic illnesses: 6.3%.
Vaccination coverage (in %) of children of 12 to 23 months	<ul style="list-style-type: none"> • BCG: 98.4% • MMR: 90.4% • Completely vaccinated children: 89.1%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

3.1.1 Healthcare system

The Ministry of Health (MoH) is responsible for the development and implementation of government policy on population health. The MoH works in conjunction with relevant departments to promote health at a national level. This is very significant because the public healthcare system (health care resources of the Ministry of Health, the Royal Armed Forces, Local Communities and other Ministerial Departments) accounts for the majority healthcare services provided in the country (Table 8) [6, 7].

In order to improve the healthcare in Morocco the government has come up with a sector wise strategy for the period of 2012 to 2016 [4]. Under this program the



main areas of actions are restructuring of medical emergencies, improvement of communicable and non-communicable disease management including mental health and cancers, consolidation of rural health, fight against maternal and infant mortality, increasing access of RAMED insurance (medical assistance scheme for poor people), improving human resource management and upgrade of hospitals. The development of a national drug policy and review of drug prices are also among the priorities [4] of MoH.

Healthcare in Morocco is generally provided via three strategies: fixed, mobile, and roaming. In the fixed strategy, the patient approaches a basic healthcare provider. The mobile and roaming strategies are implemented to cover the rural regions. In the mobile healthcare strategy a medical team periodically visits areas located far from health centers. In the roaming strategy, a nurse or a health worker visits far flung areas to distribute certain medicines like oral rehydration sachets, contraceptive pills, eye cream, etc. and to promote healthcare procedures for pregnant women, diabetics, and other chronic diseases.

The public healthcare delivery system in Morocco can also be categorized into different levels depending on the level of expert services provided by the hospital [6]. There are 2,626 basic health centers, 138 hospitals, 97 general hospitals, 37 specialized hospitals, and 4 university medical colleges (at Rabat, Casablanca, Fez, and Marrakech). The public health service infrastructure comprises 27,350 beds and 38,000 healthcare professionals (HCPs) [6]. The private medical establishments approximately include 220 clinics, 30 dialysis centers, and about 100 radiologist’s offices, which together account for 6,156 beds and 10,800 HCPs [6]. The private non-profit healthcare delivery structure accounts for only a minor share of healthcare delivery in Morocco (1,874 beds) (Table 8) [6].


Table 8: Breakdown of healthcare delivery in public and private sectors

Sector	Hospital beds, n (%)	Healthcare professionals employed, n (%)
Public	27,350 (77%)	38,000 (78%)
Private	6,156 (18%)	10,800 (22%)
Public autonomous and NGOs	1,874 (5%)	NA

Source: WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]



Figure 2: Breakdown share of hospital beds (A) in public and private hospitals



Source: WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]

Figure 3: Health care professionals (B) in public and private hospitals



Source: WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]

The Basic Healthcare Centers provide health and hygiene services to the population in both rural and urban areas. The different activities or services that are provided in these centers include: birth assistance, dental consultations and dental care, emergency care, general medical consultations, hospitalization, laboratory examinations, mental health, radiological examinations, school hygiene, specialized medical consultations, testing and water treatment [6].


As per the World Health Organization (WHO), based on data of year 2000, the total healthcare expenditure in Morocco amounts to approximately MAD 19 billion (i.e., ~5% of GDP), of which 51.6% is financed by households (out of pocket) independently and 44.4% by collective financing (taxes, insurance, and local authorities) (Figure 4) [7]. At the end of 2008, the total healthcare expenditure in

Morocco has an elaborate network of primary healthcare centers to tertiary hospitals. Public hospitals account for majority of healthcare in Morocco.



Morocco was USD 4.3 billion for the year, which was 5.6% of the GDP [6]. The analysis of spending shows that the national healthcare system spends more than 33.6% of its monetary resources on buying medicine and medical goods indicating the enormous potential for the pharmaceutical industry. Ambulatory care, including health promotion check-ups and external consultations, represents 35.2% of spending [6].

Figure 4: Financing of total health expenditure in Morocco



MoH has a national sanitary information system (SNIS) for gathering information and managing maternal and childhood health programs [8]. It is a computer program-based, system which allows data entry and validity, synthesizing graphs for different activities as well as a control panel for decision making. The data transmission from basic health structure to central level is made electronically, which are accessible for consultation to all structures of the Health Ministry. However, there seems to be a lack of integration of different health information and management systems [8].




4 Market access

4.1 Health insurance system

The MoH offers the entire population access to clinics, health centers, dispensaries, diagnostic centers, and public hospitals [9]. All Moroccans are eligible to receive care at MoH facilities. Through their local government, the poor can obtain a *certificat d'indigence*, which permits them to receive free care at public health facilities [9]. Those who are not eligible to receive *certificat d'indigence* can also receive subsidized healthcare at MoH facilities. However, concerns exist over the quality of care at these facilities, and hence people tend to prefer private healthcare providers.

The government of Morocco has initiated two major healthcare insurance packages: AMO and RAMED. The *Assurance Maladie Obligatoire* (AMO) is a payroll-based mandatory health insurance plan for public and formal private-sector employees. The *Régime d'Assistance Médicale* (RAMED) is a publicly financed fund to cover healthcare services for the poor. Both reforms are aimed at improving the access to healthcare [9]. In 2007, INAYA was introduced as a scheme that would fill the gaps left by AMO and RAMED; it provided coverage to the self-employed population. Each of these schemes are intended to cover nearly one-third of the Moroccan population (Figure 5) [7]. However, of recently INAYA is being merged with AMO. The regulatory body overseeing the operations of health insurance schemes in Morocco is *Agence Nationale de l'Assurance Maladie* (ANAM; English: National Health Insurance Agency) [7].

Figure 5: Intended coverage of population by insurance scheme



Source: WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]




4.1.1 AMO: Mandatory health insurance (*Assurance Maladie Obligatoire*)

AMO is a basic medical coverage (insurance) scheme under law No 65-00; it is the basis of social health protection in Morocco. The scheme came into effect on January 4, 2005 [7]. The beneficiaries under AMO include:

- Officials and civil servants of the state, local authorities, public health facilities, and corporations registered under public law
- Persons subject to the social security scheme in the private sector
- Pensioners in both the private and public sectors

Currently, there are more than 6,000,000 members and over 8,600,000 beneficiaries (4,600,000 in the private sector and 4,000,000 in the public sector), excluding former resistance fighters, students, etc. AMO is managed by the *Caisse nationale de Sécurité Sociale* (CNSS; English: National Social Security Fund) for nearly 2,800,000 private sector employees, and, by private insurance companies for the remainder 1,800,000 private sector employees. *Caisse nationale des Organismes de Protection Sociale* (CNOPS; English: National Fund for Social Welfare Bodies) provides AMO health insurance to nearly 3,200,000 public sector employees, while the Royal Armed Forces cover the 800,000 military personnel (Figure 6) [7].

Figure 6: Share of AMO coverage by insurance provider



Source: WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]



For insured persons and their dependents, AMO guarantees coverage for the risks and costs of healthcare associated with disease or accidents, maternity, and physical or functional rehabilitation. More specifically, AMO covers all the following for both the public and private sectors [7]:


- Childbirth
- Medical/surgical hospitalization, including day care services
- Management and follow-up care of long-term conditions and long and expensive conditions
- Monitoring of pregnancy, delivery, and postpartum care
- Well-child care up to the age of 12
- Medical devices and implants required for different medical and surgical procedures
- Refundable prosthetic devices and braces
- Refundable medicines required for the above care

For the public sector employees, the package also includes outpatient care and examination (medical consultations, laboratory tests, medical imaging/functional explorations, medicines, etc.). The funding for the insurance premiums is equally shared between employer and employee up to a fixed ceiling. Care is billed on the basis of national reference fees and tariffs set by ANAM.

Furthermore, CNSS owns a chain of polyclinics: with 1000 hospital beds, 42 operating rooms, 11 maternity centers, 13 ICUs, 9 dialysis centers, 13 medical laboratories, 137 medical imaging scanners, 1 neonatal resuscitation department, 2 cardiology intensive care units, and 10 rehabilitation units. CNSS hospitals are open to all patients and those insured by the various private companies. As per 2012 data, almost 29% of CNSS beneficiaries were under long-term care (Figure 7 & 8), and this long-term care accounted for 61% of the total benefits paid out by CNSS (Figure 7 & 8) [10].




Figure 7: CNSS pay-outs for short-term, long-term, and family care (A)



Source: CNSS, M. Key figures. 30th April, 2014]

Figure 8: CNSS beneficiaries receiving short-term, long-term, and family care (B)



Source: CNSS, M. Key figures. 30th April, 2014]

Financially, the income of the two insurance organizations (CNSS, CNOPS) for employees stands at (for the year 2012) 8.11 billion MAD, but they spend about 5.30 billion MAD on benefits. Majority of the expenditure happens for the long-term conditions (ALD) and lengthy and costly diseases (ALC), which alone constitute more than 50% of overall spending. The breakdown of revenue and expenditure per organization is given in Table 9 [11]. The major expenses under AMO are accounted by medications (33%), hospitalizations (16%) and dialysis (12%) [11].

These cost factors indicate that chronic diseases while accounting for fewer cases still command higher expenses. With the majority of the population shifting to middle and old age in coming decades, the burden of chronic diseases is expected



to increase in Morocco: healthcare funding should follow. Providing appropriate healthcare solutions to long term conditions of cardiovascular, diabetes, cancers and autoimmune conditions would become a focus for MoH in coming near future and also would provide opportunities for private enterprises.

Table 9: Breakdown of income and major expenditure of CNSS and CNOPS for 2012

Parameter	CNSS	CNOPS	Total
Income (billion MAD)	3.767	4.340	8.107
Planned expenditure (billion MAD)	1.795	3.506	5.301
Spending for ALD/ALC	58.7%	45.9%	49.9%
Drug expenditure	33.3%	33.4%	33.3%

Source: ANAM, Roadmap 2014-18. 2014

4.1.2 RAMED: Medical assistance scheme (*Régime d’Assistance Médicale*)

RAMED is a basic medical coverage scheme intended for deprived sections of the society; it was introduced in 2002 under law No 65-00. Under this scheme, individuals with a *certificat d’indigence* (English: certificate of indigence) can access free care at public healthcare and hospital facilities.

Under RAMED, households with an income of less than MAD 300 (US\$34) per capita per month will be eligible for free health insurance. Households with monthly per capita income of MAD 300–600 (US\$34–\$68) will purchase insurance based on a slab scale. To protect the poor from financial burden, there are no caps on coverage [9]; however, they can only access care at public healthcare hospitals. The following categories of people are eligible for RAMED [7]:

- Persons not covered by a basic AMO scheme and without sufficient resources to meet the costs of medical care for themselves and/or their spouse(s)
- Dependents, that is, non-wage earning children aged up to 21, who are not otherwise covered by the basic AMO scheme (age limit may be extended up to 26 in the event of prolonged illness with adequate justification)



- Children with physical disabilities, irrespective of age, who are totally and permanently unable to fulfil a remunerated activity as a result of a physical or mental incapacity
- Residents of charitable institutions, orphanages, hospices, rehabilitation facilities, and any non-profit public or private care facility accommodating abandoned children or adults with no family
- Prisoners
- Persons who have no permanent place to reside

The estimated population eligible under RAMED is at 8.5 million, including 4 million in absolute poverty. The scheme is managed and regulated by ANAM. Financially, the income of the RAMED insurance scheme stands at (for the year 2012) 1.9 billion MAD, while spending about 1.06 billion MAD on benefits. The major contributors for RAMED funding are local authorities (177 million MAD), vulnerable population/beneficiaries (136 million MAD) and government (1,611 million MAD). Just like under AMO the majority of the expenditure under RAMED happens for the long-term conditions (ALD) and lengthy and costly diseases (ALC), which alone constitute more than 50% of overall spending. This again highlights the economic burden imposed by chronic medical conditions which need early diagnosis and management in order to prevent cost overruns in late stages: an opportunity for relevant players in the healthcare industry. The breakdown of revenue and expenditure per organization is given in Table 10 [11].

Table 10: Breakdown of income and major expenditure of RAMED for 2012

Parameter	RAMED
Income (billion MAD)	1.924
Planned expenditure (billion MAD)	1.065
Spending for ALD/ALC	31%

Source: ANAM, Roadmap 2014-18, 2014

4.1.3 INAYA: Health insurance for the self-employed

INAYA was introduced in 2007 to fill in the gaps left by the existing AMO and RAMED schemes. Now this scheme is being merged with AMO. INAYA scheme was aimed at providing health coverage to the self-employed (craftsmen and retailers with or without business premises and their assistants) and freelance professionals. The estimated population eligible under the scheme is around 10



million [7]. Considering the fact that self-employed people constitute nearly one-third of the Moroccan population, this process constitutes a major expansion of the healthcare insurance system in Morocco [12]. Funding for this scheme is expected to come from the premiums to be paid by the beneficiaries.

The population covered by health insurance reached 10.8 million beneficiaries by 2012, or 33.7% of Morocco's population, as against 25% in 2006. The insurance management bodies spent 8.2 Billion MAD (excluding administrative costs), or 762 MAD/ year per beneficiary, as against 602 MAD/ year per beneficiary in 2006 [4]. However, the public hospitals, despite representing more than 80% of national bed capacity, only receive 9.8% of insurance spending in the context of direct payments and 6.6% of the total health insurance spending [4]. Furthermore, the rural areas are facing a human resource crunch as the majority of healthcare professionals (22% of public physicians and 50% of private physicians) are concentrated in Greater Casablanca and Rabat areas [4].

Morocco has an elaborate system of health insurance schemes. These schemes though successful yet need to cover nearly 50% of population. Majority of insurance expenditure is incurred on long term care.



4.2 Drug prescribing and dispensing practices

The physicians generally prescribe the drugs that are reimbursed. However, they do have the liberty to prescribe non-reimbursed drugs, in which case the patient will have to pay for themselves. There are also situations wherein the physician has to prescribe drugs that are not yet licensed in Morocco and that will have to be imported, however, with special approval from the MoH. In such cases, the physician must be able to justify his decision with evidence of efficacy and benefit for the patient. At public hospitals, an in-house pharmaco-vigilance committee assesses the need for new drugs and recommends them to the MoH for purchase. The drug, if approved, would then be purchased by the MoH for the hospital [12]. However, in the private sector, the patients are left to find and purchase the drug themselves from a private pharmacy. As per law, the health insurance providers and NGOs are not supposed to provide drugs themselves [12].



4.3 Comparison of regional regulatory agencies and environment

Medicine Regulatory Agencies (MRA) in Africa face significant challenges in meeting their mandate. Their pharmaceutical regulatory capacity is below that of Europe, Latin America, and Asia. A 2004 WHO study reported that 90% of African MRAs lacked sufficient capacity to guarantee the quality, efficacy, and safety of medicines in their country [13]. A study conducted by WHO in 2006 concluded that among African countries, only South Africa had a fully functional MRA. The MRAs of Nigeria, Zimbabwe, Senegal, Tunisia, Morocco, and Algeria were functional but needed strengthening in regulation of clinical trials. The MRAs of Ghana, Egypt, Uganda, and Ethiopia had “potential“ although they were not yet fully functional [13].

African MRAs traditionally have focused on assessment of generic products. For the review of innovative products they have relied mainly on Western MRAs [14]. However, off recently more and more products are being developed specifically for the African market. This has put African MRAs under pressure to develop their skills and capabilities in regulatory services. In general, a drug that is already approved by one of the western MRAs (such as the European Union (EU)'s EMEA or the US FDA) will find it comparatively easier to receive approval in Morocco as well. Given the absence of well-established MRAs in the African countries, pharmaceutical product development companies/organizations use various alternative routes for registration of generic/innovative drugs [14].

i. Western regulatory approval

- Routine regulatory approval

The majority of new products are first registered with well-established Western regulatory authorities (US FDA, EU EMEA, UK Medicines etc) even for the products that are likely to have little or no use in the West but are crucial for developing countries. Under this approach, companies wait for FDA or EMEA approval following which they submit the dossier to African MRAs for approval.

- Orphan drug legislation

Orphan drug legislation in the US, EU, Japan, and Australia provides incentives for manufacturers to develop drugs for diseases that have too few patients to constitute a profitable market. Under this channel approvals may be given even without large-scale clinical trials.

- Expedited approvals

- Accelerated approval (US FDA)/ Conditional approval (EU EMEA)
- Priority review (US FDA)/ Fast Track (EU EMEA)



- Fast Track (US FDA)
- ii. Neglected disease specific pathways
 - EMEA Article 58

This mechanism was established by the European Commission in 2004 to facilitate developing-country registration of medicines of major public health interest, and not for a formal registration.
 - WHO prequalification

This initiative was started in 2001 as a means to assure the quality of drugs procured through the UN system. Many African MRAs rely heavily on the WHO drug pre-qualification system as a proxy dossier assessment and, in some cases, the MRA quickly approve products that have received WHO prequalification. The program was earlier stipulated for drugs for HIV/AIDS, malaria, and tuberculosis; however, it has now invited companies to submit products for reproductive health, influenza, and zinc supplements.
 - US FDA “tentative approval” and PEPFAR

As part of the US President’s Emergency Plan for AIDS Relief program (PEPFAR), the US FDA would evaluate the safety, efficacy and quality of HIV drugs purchased with PEPFAR funds for use outside the US.
- iii. Alternative regulatory pathways
 - Parallel Western and developing country approval

Under this the companies submit full dossiers to the Western regulator and developing country MRAs, both of who conduct their regulatory reviews simultaneously but independently.
 - Twinned Western and developing country approval

Twinned review refers to a process whereby a developing country regulator would assess a pharmaceutical dossier in consultation with, a well-resourced western regulatory agency.
 - First approval by a developing country regulator

Under this approach, the company submits the dossier first to a developing country regulator, usually their home regulator.
 - WHO vaccine prequalification

The WHO Vaccine Prequalification program was set up in 1987 as a service to UNICEF and other UN vaccine procurement agencies. It aims to



determine that products bought by these agencies and used in national immunization services are safe, effective, and meet operational and quality standards. The African governments rely heavily on WHO vaccine pre-qualification.

The complex African regulatory environment had led to difficulties in optimal use of resources by the MRAs. Therefore, a great deal of effort is being committed to African regulatory harmonization. To this end, various communities are being formed, including the following [13]:

4.3.1 Southern African Development Community (SADC):

SADC was formally established by treaty in Namibia on August 17th, 1992. It consists of 15 member states (Angola, Botswana, Democratic Republic of the Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe), and aims to share resources and expertise among various MRAs, provide training, develop guidelines, harmonize clinical trials etc. [13].

4.3.2 Economic Community of West African States (ECOWAS):

ECOWAS is a West African Drugs Regulatory Authority Network (WADRAN) of Anglophone and francophone West African states for fighting counterfeit medications, evaluating dossiers, and conducting Good Manufacturing Practices investigations and surveillance after registration of drugs [13].

4.3.3 East African Community (EAC):

EAC is working toward harmonization of drug registration procedures as an objective to achieve good pharmaceutical standards without posing an obstacle to the free movement of pharmaceutical products [13].



4.4 Drug approval and reimbursement process in Morocco

Any drug, either produced locally or imported, even at the sample level, must obtain authorization from the Department of Pharmacy, MoH, prior to sale or distribution (even for free) [15]. Moreover, this authorization is necessary before any drug can be considered for reimbursement. The MoH states that authorization can only be issued if the drug meets certain prerequisites for appropriate testing to highlight efficacy, ensure its safety under normal conditions of use, demonstrate its therapeutic value, and establish bioequivalence when it comes to a generic drug. Thus, the manufacturer can show the clinical trial data of the drug to showcase its safety and efficacy parameters [15]. However, if the drug has already been proven to be efficacious and has been approved by one of the Western regulatory agencies (US FDA or EU EMEA), then the approval process for Morocco will be greatly accelerated. The intellectual property protection laws in Morocco are comparatively better; a generic drug can only be sold when the patent of the reference drug expires [15].

ANAM is the regulatory agency responsible for insurance reimbursement in Morocco. For a new drug to be approved for reimbursement, it must pass through two stages of evaluation. First, ANAM's *Transparency Committee* assesses new drugs based on their efficacy and superiority to existing strategies of treatment. The Transparency committee assesses new drugs based solely on efficacy and safety parameters and not based on cost parameters. The committee accepts the clinical trial data from other countries and it is not necessary in every case to conduct a study in the host country for drug reimbursement. If the application passes this stage, it is sent to the *Economic Committee* to assess the cost implications. The recommendations of both committees are taken into account before ANAM submits reimbursement recommendations to the MoH for approval. Currently, of the approximately 5,000 drug formulations approved for distribution in Morocco, reimbursement is available for 3,000 drug formulations [12].

While the Economic Committee falls directly under the purview of ANAM, the Transparency Committee is an independent body associated with ANAM. The members of the Transparency Committee include a president and vice-president, who are appointed by the MoH; representatives from the National Organization of Humanity and Ethics and from the Ethics Organization of Physicians and Pharmacists; the Department of Pharmacy and Drugs; and four independent expert physicians nominated by ANAM [12]. The expert physicians are permanent members, but can recommend other external experts, if a certain drug is outside their scope of expertise.


Drug prices in Morocco are controlled and the policy guidelines tend towards lower prices for certain important therapeutic classes. Generally, drugs that could have a major impact on key public health issues can be expected to suffer significant cost pressures. If the price of the drug is beyond the scope of the planned budget, then the committee might ask the manufacturer to reduce the price [12]. However, the MoH is currently proposing a new system to [15]:

ANAM is the key regulatory body tasked with approval of new drugs and with approval of reimbursement for drugs.



- Establish an updated regulatory framework for products with local manufacturing and imported products
- Improve access to medicines while containing costs
- Provide solutions to national pharmaceutical environment

Figure 9: Drug approval and reimbursement process in Morocco



Source: CNSS, M. Key figures. 30th April, 2014]



5 Conclusion

Morocco, officially known as the Kingdom of Morocco, is a constitutional monarchy with an elected parliament in the Maghreb region of North Africa. The majority of its population belongs to the economically productive age group of 25–54, which also makes the country economically robust. In Morocco, public healthcare systems account for the majority of healthcare services provided. However, organized-sector workers such as private and public sector employees prefer private clinics over public hospitals, as they are reimbursed under the AMO scheme. It is in private hospitals that the majority of insurance reimbursement happens. The poor (those holding a certificate of indigence) are provided free medical care at public hospitals under RAMED, which is financed directly by the government. However, the healthcare services under RAMED are limited as compared with those under AMO, and, moreover, RAMED does not provide reimbursement, only free treatment. Nearly 50% of Moroccans are covered by some form of medical insurance (~30% by AMO and ~20% by RAMED). Despite that, nearly half of the healthcare expenditure in Morocco is still out-of-pocket, as the health insurance framework is not yet completely established. With the majority of the population shifting to middle and old age in coming decades, the burden of chronic diseases is expected to increase in Morocco, so healthcare funding should do the same. Providing appropriate healthcare solutions to long term conditions of cardiovascular, diabetes, cancers and autoimmune conditions would become a focus for MoH in coming near future and also would provide opportunities for private enterprises.

Regardless of the inaccuracies in health insurance, approval for reimbursement (especially for costly and specialized therapeutics) still represents a major advantage toward achieving patient access. Furthermore, as Morocco does not have a well-established MRA, approval by a Western agency (e.g., US FDA or EU EMEA) is a very good first step toward securing approval for marketing in Morocco. An added advantage is that the Moroccan MRA, that is the Department of Pharmacy of the MoH, will approve drugs on the basis of clinical trials conducted outside the country. Physicians generally prescribe the drugs that are reimbursed. However, they do have the liberty to prescribe non-reimbursed drugs and in such cases the patient will have to pay out of their pocket for the medications.

Our analyses of the current healthcare activities in Morocco and the general trends in emerging markets shows policy makers and patient bodies are demanding greater influence in the drug selection process. As a result, a collaborative approach needs to be promoted to outline and manage public policies. It is important for each stakeholder to include scientific and rational data to support their issues and concerns. This is of particular importance in countries like Morocco, where the MoH and ANAM evaluate drugs on both efficacy and economic impact.



6 Appendix

6.1 Glossary

ALD (French)	: long-term conditions
ALC (French)	: lengthy and costly diseases
AMO	: Moroccan mandatory health insurance scheme (<i>Assurance Maladie Obligatoire</i>)
ANAM	: Moroccan National Health Insurance Agency (<i>Agence Nationale de l'Assurance Maladie</i>)
ASR	: age-standardized rate
BCG	: Bacillus Calmette-Guerin vaccine for tuberculosis
CNOPS	: Moroccan National Fund for Social Welfare Bodies (<i>Caisse nationale des Organismes de Protection Sociale</i>)
CNSS	: Moroccan National Social Security Fund (<i>Caisse nationale de Sécurité Sociale</i>)
EAC	: East African Community
ECOWAS	: Economic Community of West African States
ESMO	: European Society for Medical Oncology
EMA	: European Medicines Agency
EU	: European Union
FSRC	: focus scientific research center
GDP	: gross domestic product
HCP	: healthcare professional
HDI	: human development index
HDR	: human development reports
INAYA	: Moroccan health insurance scheme for self-employed
MAD	: Moroccan dirham
MMR	: Measles Mumps and Rubella vaccine
MoH	: Moroccan Ministry of Health
MRA	: Medicine Regulatory Agencies
NATO	: North Atlantic Treaty Organization
NGO	: non-governmental organization
PEPFAR	: US President's Emergency Plan for AIDS Relief



PET	: positron emission tomography
PPP	: purchasing power parity
RAMED	: Moroccan publicly financed fund for healthcare services to the poor (<i>Régime d'Assistance Médicale</i>)
SADC	: Southern African Development Community
UNDP	: United Nations Development Programme
UNESCO	: United Nations Educational, Scientific and Cultural Organization
US	: the United States of America
USD	: United States dollar
FDA	: Food and Drug Administration (US)
WHO	: World Health Organization



6.2 Coverage rates for long-term and costly conditions

Table 11: Coverage rates for long-term and costly conditions

Long lasting diseases	Diseases	New reimbursement rate
Malignancies	Malignancies	95%
Malignancy of the lymph tissue or haematopoietic tissue	Malignancy of the lymph tissue or haematopoietic tissue	95%
Liver cirrhosis	Liver cirrhosis	97%
Active chronic liver disease (Hepatitis B and C)	Active chronic liver disease (Hepatitis B and C)	97%
Terminal stage of renal disease	Terminal stage of renal disease	98%
Severe Aplastic	Severe Aplastic	99%
Hereditary bleeding disorders	Hereditary bleeding disorders	97%
Severe myelodysplasia	Severe myelodysplasia	94%
Multiple Sclerosis	Multiple Sclerosis	96%
Stroke or ischemic or haemorrhagic medullary	Stroke or ischemic or haemorrhagic medullary	90%
Chronic respiratory insufficiency	Severe chronic respiratory insufficiency	90%
Coronary disease	Stable angina	85%
	Revascularized coronary (Angioplasty or bypass)	85%
	Unstable angina or syndrome	85%
	Acute Myocardial Infraction (MI)	85%
Chronic hemolytic anemia severe	Thalassemia major	96%
	Homozygous sickle cell	96%
	Chronic autoimmune hemolytic anemia	96%
Severe asthma	Moderate to severe chronic asthma	90%
	Severe asthma episodes	90%
	Acute Severe Asthma	90%



Long lasting diseases	Diseases	New reimbursement rate
Rheumatoid polyarthritis	Rheumatoid arthritis severe progressive	93%
Severe kidney disease	Glomerulonephritis	96%
	Pyelonephritis	96%
	Renal interstitial	96%
	Renal vascular	96%
	Hereditary kidney disease or congenital	96%
Nephrotic syndrome	Nephrotic syndrome	96%
Acute renal failure	Acute renal failure	95%
Heart failure	Left ventricular failure	83%
	Right ventricular failure	83%
Ulcerative colitis	Ulcerative colitis	81%
Crohn`s disease	Crohn`s disease	81%
Systemic lupus erythematosus	Systemic lupus erythematosus	97%
Severe epilepsy	Severe epilepsy	97%
	Status epilepticus	97%
Progressive systemic sclerosis	Progressive systemic sclerosis	91%
Vasculitis	Vasculitis	93%
Mental disorders and /or personality due to an injury, a brain dysfunction or physical injury	Mental disorders and /or personality due to an injury, a brain dysfunction or physical injury	83%
High blood pressure (hypertension) severe	HTA with high CV risk	77%
	Hypertension with LVH	77%
	HTA with IC	77%
	HTA with myocardial ischemia	77%
	HTA with IR	77%
	Hypertension with hypertensive retinopathy	77%
	HTA with ATCD stroke	77%



Long lasting diseases	Diseases	New reimbursement rate
	HTA with ATCD transient ischemia	77%
	With arterial hypertension Member lower	77%
Severe forms of the neurological and neuromuscular disease	MM hereditary myopathy	85%
	MM Inflammatory Myopathy	85%
	MM Myasthenia	85%
	MM SD Lambert-Eaton	85%
	The MNP-polyneuritis	85%
	MNP-Multiple mononeuropathy	85%
	MNP-polyradiculoneuritis	85%
	MNP-Hereditary neuropathy	85%
	The spastic paraparesis MMCA-family	85%
	MMCA-Charcot's disease (ALS)	85%
The hereditary ataxias MMCA	85%	
State mental deficit	Mental retardation	83%
	Acquired dementia :Alzheimer's disease	83%
	Secondary dementias	83%
Glaucoma	Glaucoma	83%
Acquired Immunodeficiency Syndrome (AIDS)	Acquired Immunodeficiency Syndrome (AIDS)	85%

Source: ANAM website; http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=18#38



Table 12: Coverage rate of lasting and costly disorders

Procedure	Break down	Coverage rate
Organ transplantation	Kidney	100%
	Liver	100%
	Heart	100%
	Cornea	100%
	Bone Marrow	100%
Cardiac surgery	Rheumatic valvular	100%
	Congenital heart	100%
	Coronary disease	100%
	Laying Pace Maker	100%
	Chronic arterial disease	100%

Source: ANAM website; http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=18#38



6.3 Essential drug list of Morocco

Table 13: Essential drug list of Morocco

Class Therapeutic	CODE	Name Common International	Packaging
Metabolism --Hematology -- Diabetes --Nutrition	200100103	Acarbose 100Mg Tablet	Box Of 90 Tablets
Cardiology - Medicines	1120010103	Acenocoumarol 4Mg Tablets	Box Of 100 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	DMP93	Acetyl Salicylate Lysine 100Mg Bag	Box Of 20 Packs
Cardiology - Medicines	DMP18	Acetyl Salicylate Lysine 160Mg Bag	Box 30 Packs
Analgesics --Antipyretics -- Anti- Inflammatory	DMP17	Acetyl Salicylate Lysine 1G Injection	Box Of 6 Bottles + Solvent
Analgesics --Antipyretics -- Anti- Inflammatory	DMP89	Acetyl Salicylate Lysine 250Mg Bag	Box Of 20 Packs
Cardiology - Medicines	DMP188	Acetyl Salicylate Lysine 300Mg Bag	Box 30 Packs
Infectious disease	DMP19	Aciclovir 200Mg Tablet	Box Of 25 Tablets
Infectious disease	DMP20	Aciclovir 250Mg Injection	Box 1 Bottle
Ophthalmology	DMP190	Aciclovir 3% Ophthalmic Ointment	Tube 4.5 Billion
Dermatology	DMP195	Aciclovir 5% Cream	Tube 10 G
Analgesics -- Antipyretics -- Anti- Inflammatory	1000010103	Acid 500Mg Tablets Acetylsalicylic	Box Of 1000 Tablets
Rheumatology	1010070103	Alendronique Acid 70Mg Tablets	Box Of 4 Tablets
Dermatology	2010000201	Fusidic Acid 2% Ointment Or	Tube 15 G



Class Therapeutic	CODE	Name Common International	Packaging
		Cream	
Infectious disease	4000250103	Fusidic Acid 250Mg Tablet	Box Of 10 Tablets
Anesthesia - Resuscitation	100010201	Adrenaline Injection 0.25Mg	Box 100 Bulbs
Anesthesia - Resuscitation	DMP1	Adrenaline Injection 0,50Mg	Box 100 Bulbs
Anesthesia - Resuscitation	100020201	Adrenaline Injection 1Mg	Box 100 Bulbs
Infectious disease	440210106	Albendazole 4% Oral Suspension	Bottle 10MI
Infectious disease	440200103	Albendazole 400Mg Tablet	Box 1 Tablet
Rheumatology	1020010103	Allopurinol 100Mg Tablet	Box Of 100 Tablets
Rheumatology	1020030103	Allopurinol 300Mg Tablet	Box Of 28 Tablets
Pneumology	120300506	Ambroxol 0.3% Syrup	Bottle 150MI
Products Contrast	DMP21	Amidotrizoate De Sodium And De Meglumine 30% Injection	Bottle 250MI + Infusion
Products Contrast	DMP106	Amidotrizoate De Sodium And De Meglumine 76% Injection	Bottle 50MI + Infusion
Infectious disease	DMP23	Amikacin 250Mg Injection	Box + 1 Vial Solvent
Infectious disease	DMP3	Amikacin 500Mg Injection	Box + 1 Vial Solvent
Cardiology - Medicines	720040501	Amiodarone 150Mg Injection	Box Of 6 Bulbs
Cardiology - Medicines	DMP24	Amiodarone 200Mg Tablet	Box Of 40 Tablets
Psychiatry - Neurology	1220020103	25Mg Tablets Amitriptyline	Box Of 60



Class Therapeutic	CODE	Name Common International	Packaging
			Tablets
Psychiatry - Neurology	DMP84	Amitriptyline 4% Sol Oral	Bottle 20ML
Cardiology - Medicines	780051003	10Mg Tablets Amlodipine	Box Of 28 Tablets
Cardiology - Medicines	780050103	Amlodipine 5Mg Tablet	Box Of 28 Tablets
Infectious disease	4100125105	Amoxicillin 125Mg + Acid Clavulanic Powder To Suspension Oral	Bottle 60ML
Infectious disease	410010105	Amoxicillin 125Mg Powder To Suspension Oral	Box Of 10 Bottles 60ML
Infectious disease	DMP140	Amoxicillin 1G + Acid Clavulanic Injection	Box Of 10 Bottles
Infectious disease	410010001	Amoxicillin + 1G Clavulanic Acid Bag	Box 14 Packs
Infectious disease	410010003	Amoxicillin 1G Tablets	Box Of 24 Tablets
Infectious disease		Amoxicillin 1G Injection	Box 1 Bulb
Infectious disease	410720501	Amoxicillin 250Mg + Acid Clavulanic Powder To Suspension Oral	Box 1 Bottle 60ML
Infectious disease	410030105	Amoxicillin 250Mg Powder To Suspension Oral	Box Of 10 Bottles 60ML
Infectious disease	DMP25	Amoxicillin 500Mg + Acid Clavulanic Tablets	Box Of 24 Tablets
Infectious disease	4100500501	Amoxicillin 500Mg + Acid Clavulanic Injection	Box 1 Bottle
Infectious disease	410040103	Amoxicillin 500Mg Tablet Or	Box De 24



Class Therapeutic	CODE	Name Common International	Packaging
		Capsule	Tablets Or Capsules
Infectious disease	DMP107	Amphotericin B 10% Oral Suspension	Bottle 40Ml
Infectious disease	450050501	Amphotericin B Injection 50Mg	Bottle 15Ml
Infectious disease	410050505	Ampicillin 1G Injection	Box Of 50 Bottles + Solvent
Infectious disease	410060505	Ampicillin 250Mg Injection	Box Of 50 Bottles + Solvent
Infectious disease	410070505	Ampicillin 500Mg Injection	Box Of 50 Bottles + Solvent
Pneumology	820010106	Antitussive Central Syrup Adult To Base De Codeine, Codethylene, Pholcodine Or	Box Of 25 Bottles 125Ml
Cardiology - Medicines	DMP101	Atenolol 100Mg Tablet	Box Of 28 Tablets
Anesthesia - Resuscitation	100060201	Atracurium Injection 50Mg	Box Of 10 Bulbs
Anesthesia - Resuscitation	100060501	Atracurium Injection 25Mg	Box Of 10 Bulbs
Anesthesia - Resuscitation	640010601	Atropine 0.25Mg Injection	Box 100 Bulbs
Anesthesia - Resuscitation	640050601	Atropine 0,50Mg Injection	Box 100 Bulbs
Anesthesia - Resuscitation	640070601	Atropine 1Mg Injection	Box 100 Bulbs
Pneumology	DMP26	Aerosol Beclomethasone 50Mg	Bottle 200 Doses
Infectious disease	410100505	Benzathine Benzylpenicillin 0,6MIU Injection	Box Of 50 Bottles + Solvent
Infectious disease	410080505	Benzathine Benzylpenicillin	Box Of 50



Class Therapeutic	CODE	Name Common International	Packaging
		1,2MIU Injection	Bottles + Solvent
Dermatology	440011207	Benzoate De Benzyl 10% + Sulfiram 2% Solution Skin	Box Of 25 Bottles 150MI
Infectious disease	410290505	Benzylpenicillin 1MIU Injection	Box Of 50 Bottles + Solvent
Infectious disease	410280505	Benzylpenicillin 5MIU Injection	Box Of 6 Bottles + Solvent
Infectious disease	410270305	Benzylpenicillin Procaine 1MIU Injection	Box Of 50 Bottles + Solvent
Analgesics --Antipyretics -- Anti- Inflammatory	DMP27	Betamethasone 4Mg Injection	Box 3 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	DMP28	Betamethasone 8Mg Injection With Syringe And Needle Sterile	Box 1 Bulb
Dermatology	2300011215	Biogaze Dressing Compresses	Box Of 20 Compresses
Cardiology - Medicines	820010103	10Mg Tablets Bisoprolol	Box Of 28 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	200025103	Bromocriptine 2.5 Mg Tablets	Box Of 30 Tablets
Anesthesia - Resuscitation	640010501	N-Butyl Bromide 10Mg Tablets Of Hyoscine	Box Of 40 Tablets
Anesthesia - Resuscitation	640010105	Bromide N-Butyl Hyoscine 10Mg Suppositories	Box Of 6 Suppositories
Anesthesia - Resuscitation	640020501	N-Butyl Bromide For Injection 20Mg Hyoscine	Box Of 50 Bulbs
Anesthesia - Resuscitation	210011107	Bupivacaine 0.25% Injection	Bottle 20MI
Anesthesia - Resuscitation	210051107	Bupivacaine 0.50% Injection	Bottle 20MI



Class Therapeutic	CODE	Name Common International	Packaging
Anesthesia - Resuscitation	260011105	Buprenorphine 0.3Mg Injection	De10 Bulbs Box
Metabolism --Hematology -- Diabetes --Nutrition	20005103	Cabergoline 0.5 Mg Tablets	Box 8 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	2100010103	Calcium Tablets Effervescent 1G	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	2100500103	Calcium 500Mg + Vitamin D3 400 IU Tablets	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	2100010501	Calcium Injection 87Mg	Box 5 Bulbs
Cardiology - Medicines	820020103	25Mg Tablets Captopril	Box Of 30 Tablets
Cardiology - Medicines	DMP120	50Mg Tablets Captopril	Box Of 30 Tablets
Psychiatry - Neurology	1240010103	Carbamazepine 200Mg Tablet	Box Of 50 Tablets
Psychiatry - Neurology	1240120103	Carbamazepine 400Mg Tablet	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	960010103	Carbimazole 5Mg Tablet	Box Of 50 Tablets
Pneumology	DMP6	Carbocysteine 5% Syrup	Bottle 125Ml
Cardiology - Medicines	84000103	Carvedilol 6.25Mg Tablets	Box Of 30 Tablets
Infectious disease	DMP31	Cefalotin 1G Injection	Box + 1 Vial Solvent
Infectious disease	401100105	Cefixime 100Mg Powder To Suspension Oral	Box 1 Bottle 40Ml
Infectious disease	401040105	Cefixime 40Mg Powder To	Box 1 Bottle



Class Therapeutic	CODE	Name Common International	Packaging
		Suspension Oral	40Ml
Infectious disease	40110005	Ceftazidime 1G Injection	Box 1 Bottle
Infectious disease	DMP32	Ceftriaxone 1G Injection	Box + 1 Vial Solvent
Infectious disease	DMP33	Ceftriaxone 250Mg Injection	Box + 1 Vial Solvent
Infectious disease	DMP34	Ceftriaxone 500Mg Injection	Box Of 20 Bottles + Solvent
Allergology	300010201	10Mg Tablets Cetirizine	Box Of 15 Tablets
Allergology	300010101	Cetirizine 1Mg / Ml Oral Suspension	Bottle 60Ml
Gastroenterology	600100001	Coal Assets Or Plant Tablets Or Capsules	Box De 30 Tablets Or Capsules
Psychiatry - Neurology	1210020103	Chlorpromazine 100Mg Tablet	Box Of 50 Tablets
Psychiatry - Neurology	1210160103	25Mg Tablets Chlorpromazine	Box Of 50 Tablets
Psychiatry - Neurology	1210011001	Chlorpromazine Injection 25Mg	Box 5 Bulbs
Ophthalmology	1310031619	Chlortetracycline 1% Ophthalmic Ointment	Box Of 50 Tubes 5 G
Dermatology	1810011219	Chlortetracycline 3% Ointment Skin	25 Tubes 15 G
Cardiology - Medicines	DMP39	Potassium Chloride Injection 10%	Box 100 Bulbs
Cardiology - Medicines	DMP141	Potassium Chloride Capsule	Box Of 40



Class Therapeutic	CODE	Name Common International	Packaging
		600Mg	Capsules
Infectious disease	DMP1420	200Mg Ciprofloxacin Injection	Bottle 100Ml
Infectious disease	DMP142	Ciprofloxacin Tablets 500Mg	Box Of 10 Tablets
Anesthesia - Resuscitation	100080103	Cisatracurium 10Mg / 5Ml Injection	Box 5 Bulbs
Psychiatry - Neurology	1220070103	25Mg Tablets Clomipramine	Box Of 30 Tablets
Psychiatry - Neurology	1220061001	Clomipramine Injection 25Mg	Box Of 10 Bulbs
Psychiatry - Neurology	DMP40	Clonazepam 2Mg Tablet	Box Of 40 Tablets
Cardiology - Medicines	730040501	Clonidine 0.15Mg / Ml Injection	Box Of 30 Bulbs
Cardiology - Medicines	730040105	Clonidine 0.15Mg Tablets	Box Of 20 Tablets
Cardiology - Medicines	7300750103	Clopidogrel Tablets 75Mg	Box Of 28 Tablets
Rheumatology	1020020103	Colchicine Tablets 1Mg	Box Of 40 Tablets
Dermatology	1890061202	Collargol 5% Ointment	Box 25 Tubes 5G
Ophthalmology	1340041609	Cyclopentolate 0.5% Eye Drops	Box Of 10 Bottles 0.5Ml
Oncology --Hormone Therapy - -Immunology	101004201	Cyclophosphamide 200Mg Injection	Box Of 10 Bottles
Oncology --Hormone Therapy - -Immunology	101004501	Cyclophosphamide 500Mg Injection	Box 1 Bottle
Analgesics --Antipyretics --	DMP41	Dexamethasone Tablets 0.5Mg	Box Of 40



Class Therapeutic	CODE	Name Common International	Packaging
Anti- Inflammatory			Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	DMP143	Dexamethasone Injection 5Mg	Box 3 Bulbs
Allergology	300020103	Dexchlorpheniramine 2Mg Tablet	Box Of 30 Tablets
Psychiatry - Neurology	1230020501	Diazepam Injection 10Mg	Box Of 50 Bulbs
Psychiatry - Neurology	1230040103	Diazepam 5Mg Tablet	Box Of 40 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	DMP47	Diclofenac 25Mg Suppositories	Box 10 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000141418	Diclofenac 100Mg Suppositories	Box 10 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	DMP46	Diclofenac 12.5Mg Suppositories	Box 10 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	DMP9	50Mg Tablets Diclofenac	Box Of 100 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	1000141475	Diclofenac Injection 75Mg	Box 2 Bulbs
Cardiology - Medicines	740030103	Digoxin 0.25 Mg Tablets	Box Of 30 Tablets
Cardiology - Medicines	DMP48	Digoxin 5% Oral Solution	Bottle 60Ml
Cardiology - Medicines	730030105	25Mg Tablets Dihydralazine	Box Of 40 Tablets
Cardiology - Medicines	750010901	Diltiazem 90Mg Tablets Or Capsules	Box De 30 Tablets Or Capsules
Cardiology - Medicines	710020803	Dinitrate Isosorbide 20Mg Capsules	Box Of 60 Capsules



Class Therapeutic	CODE	Name Common International	Packaging
Cardiology - Medicines	710011803	Dinitrate Isosorbide 10Mg Tablets	Box Of 60 Tablets
Cardiology - Medicines	710040103	Dinitrate Isosorbide 5Mg Tablet	Box Of 30 Tablets
Gastroenterology	6013000301	Diosmectite 3G Bag	Box 60 Packs
Cardiology - Medicines	750030103	Diosmin 300Mg Tablet	Box Of 30 Tablets
Anesthesia - Resuscitation	100130201	Dobutamine 250Mg Injection	Box 1 Bottle
Gastroenterology	DMP49	Domperidone 0.1% Oral Suspension	Bottle 200ML
Gastroenterology	DMP50	10Mg Tablets Domperidone	Box Of 20 Tablets
Anesthesia - Resuscitation	100100201	Dopamine 200Mg Injection	Box Of 20 Bulbs
Anesthesia - Resuscitation	100030201	Dopamine Injection 50Mg	Box Of 50 Bulbs
Oncology --Hormone Therapy - -Immunology	1010030205	Doxorubicin Injection 50Mg	Box 1 Bottle
Infectious disease	410700103	Doxycycline 200Mg Tablet	Box Of 10 Tablets
Solvents	2300040201	Water For Injection Preparation	Box 100 Bulbs 5ML
Dermatology	DMP510	Econazole 1% Ointment Or Cream	Tube 30 G
Gynecology - Obstetrics	DMP51	Econazole 150Mg Ova Gynaecological	Box 3 Ova
Cardiology - Medicines	750050201	20Mg Tablets Enalapril	Box Of 28 Tablets
Cardiology - Medicines	750050005	Enalapril 5Mg Tablet	Box Of 28 Tablets



Class Therapeutic	CODE	Name Common International	Packaging
Dermatology	1840061207	Eosine Disodium 2% Solution Skin	Carton Of 15 Bottles Of 1 Litre
Anesthesia - Resuscitation	100150202	Ephedrine 3% Injection	Box Of 10 Bulbs
Metabolism --Hematology -- Diabetes --Nutrition	300020510	Epoetin Alfa 2000Ui / Ml Injection	Box Of 10 Bottles
Metabolism --Hematology -- Diabetes --Nutrition	3000205065	Epoetin Alfa 2000Ui / Ml Injection	Box Of 6 Needle 0.5Ml
Metabolism --Hematology -- Diabetes --Nutrition	3000405065	Epoetin Alfa 4000Ui / Ml Injection	Box Of 6 Needle 0.5Ml
Metabolism --Hematology -- Diabetes --Nutrition	300010504	Epoetin Alfa 10000Ui / Ml Injection	Box Of 6 Needle 0.4Ml
Metabolism --Hematology -- Diabetes --Nutrition	300010506	Epoetin Beta 1000Ui Injection	Box Of 6 Needle
Metabolism --Hematology -- Diabetes --Nutrition	3000205063	Epoetin Beta 2000Ui Injection	Box Of 6 Needle
Metabolism --Hematology -- Diabetes --Nutrition	3000305063	Epoetin Beta 3000Ui Injection	Box Of 6 Needle
Metabolism --Hematology -- Diabetes --Nutrition	3000505063	Epoetin Beta 5000Ui Injection	Box Of 6 Needle
Metabolism --Hematology -- Diabetes --Nutrition	3000105063	Epoetin Beta 10000Ui Injection	Box Of 6 Needle
Infectious disease	410170116	Erythromycin 125Mg Pellet To Suspension Oral	Box 12 Packs
Infectious disease	410180103	Erythromycin Tablets 500Mg	Box Of 100 Tablets
Cardiology - Medicines	DMP540	Etamsylate 250Mg Tablet	Box Of 20 Tablets



Class Therapeutic	CODE	Name Common International	Packaging
Cardiology - Medicines	DMP54	Etamsylate 250Mg Injection	Box Of 6 Bulbs
Cardiology - Medicines	DMP55	Etamsylate 500Mg Tablet	Box Of 20 Tablets
Anesthesia - Resuscitation	100180301	Etomidate 2Mg / Ml Injection	Box 5 Bulbs
Cardiology - Medicines	7500200103	Fenofibrate 200Mg Capsules	Box Of 30 Capsules
Anesthesia - Resuscitation	DMP85	Fentanyl 100 Micrograms / 2 Ml Injectable	Box 5 Bulbs
Anesthesia - Resuscitation	DMP86	Fentanyl 500Mg / 10 Ml Injectable	Box Of 10 Bulbs
Metabolism --Hematology -- Diabetes --Nutrition	140010106	Iron Pediatric Syrup	Bottle 150Ml
Metabolism --Hematology -- Diabetes --Nutrition	140030501	Filgrastim 300Mg Injection	Box 1 Syringe
Metabolism --Hematology -- Diabetes --Nutrition	1400480501	Filgrastim 480Mg Injection	Box 1 Syringe
Infectious disease	410670105	Flucloxacillin 125Mg Oral Suspension	Box Of 10 Bottles 60Ml
Infectious disease	410510501	Flucloxacillin 1G Injection	Box Of 10 Bottles + Solvent
Infectious disease	410660501	Flucloxacillin 250Mg Injection	Box Of 10 Bottles + Solvent
Infectious disease	410680105	Flucloxacillin 250Mg Oral Suspension	Box Of 10 Bottles 60Ml
Infectious disease	410680103	Flucloxacillin 500Mg Capsule	Box Of 12 Capsules
Infectious disease	410500501	Flucloxacillin 500Mg Injection	Box Of 10 Bottles + Solvent



Class Therapeutic	CODE	Name Common International	Packaging
Infectious disease	411150103	Fluconazole 150Mg Capsules	Box Of 4 Capsules
Infectious disease	41120005	Fluconazole 2Mg / Ml Injection	Bottle 100Ml
Infectious disease	411050103	Fluconazole 50Mg Capsules	Box 7 Capsules
Ophthalmology	1340071609	Fluorescein 10% Sodium Injection	Box Of 10 Bulbs
Psychiatry - Neurology	1260020103	Fluoxetine 20Mg Capsules	Box Of 20 Capsules
Psychiatry - Neurology	1210050301	Fluphenazine Decanoate Injection 25Mg	Box Of 50 Bulbs
Pneumology	1200100506	Fluticasone + Salmeterol 100 / 50Mg Inhalation	60 Single Dose Containers
Pneumology	1200250506	Fluticasone + Salmeterol 250 / 50Mg Inhalation	60 Single Dose Containers
Metabolism --Hematology -- Diabetes --Nutrition	1130020103	Fumarate Ferrous 200Mg Tablet	Box Of 100 Tablets
Cardiology - Medicines	770020501	Furosemide Injection 20Mg	Box Of 25 Bulbs
Cardiology - Medicines	7700250501	Furosemide 250Mg Injection	Box 5 Bulbs
Cardiology - Medicines	770030103	40Mg Tablets Furosemide	Box Of 100 Tablets
Cardiology - Medicines	7700500103	Furosemide 500Mg Tablet	Box Of 50 Tablets
Ophthalmology	1310071609	Gentamicin 0.3% Eye Drops	Box Of 10 Bottles 5Ml
Infectious disease	410551205	Gentamicin 120Mg Injection	Box Of 6 Bulbs
Infectious disease	410550501	Gentamicin 160Mg Injection	Box Of 25 Bulbs
Infectious disease	410190501	Gentamicin Injection 20Mg	Box Of 25 Bulbs



Class Therapeutic	CODE	Name Common International	Packaging
Infectious disease	410200501	Gentamicin Injection 40Mg	Box Of 25 Bulbs
Infectious disease	410210501	Gentamicin Injection 80Mg	Box Of 25 Bulbs
Metabolism --Hematology -- Diabetes --Nutrition	920010103	Glibenclamide 5Mg Tablet	Box Of 100 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	920030103	30Mg Tablets Gliclazide	Box Of 60 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	920060103	80Mg Tablets Gliclazide	Box Of 60 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	1500100103	Glimepiride Tablets 1Mg	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	1500200103	Glimepiride 2Mg Tablet	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	1500300103	Glimepiride 3Mg Tablets	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	1500400103	Glimepiride 4Mg Tablets	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	1700100501	Glucagon 1Mg Injection	Box 1 Bottle
Infectious disease	450020103	Griseofulvin 125Mg Tablet	Box Of 100 Tablets
Infectious disease	DMP57	Griseofulvin 250Mg Tablet	Box Of 30 Tablets
Dermatology	DMP56	Griseofulvin 5% Ointment	Tube 15 G
Infectious disease	450030103	Griseofulvin 500Mg Tablet	Box Of 30 Tablets
Psychiatry - Neurology	1210080901	Haloperidol 5Mg Injection	Box Of 50 Bulbs
Psychiatry - Neurology	1210070109	Haloperidol 0.2% Oral Sol	Box Of 25 Bottles 15ML



Class Therapeutic	CODE	Name Common International	Packaging
Anesthesia - Resuscitation	220031310	Halothane Suspension 250Mg Inhalation	Bottle 250Ml
Cardiology - Medicines	DMP108	Heparin Sodium Injection 25 000Ui	Box De 10 Bottles Or 10 Bulbs
Cardiology - Medicines	DMP1009	Heparin To Bas Weight Molecular 2000 To3000Ui Anti-Xa, Injection	Box 2 Needle
Cardiology - Medicines	DMP870	Heparin To Bas Weight Molecular 3500 To4500Ui Anti-Xa, Injection	Box 2 Needle
Cardiology - Medicines	DMP1008	Heparin To Bas Weight Molecular 5000 To6000Ui Anti-Xa, Injection	Box 2 Needle
Other	650010107	Paraffin Oil	Carton Of 15 Bottles Of 1 Litre
Cardiology - Medicines	770070103D	Hydrochlorothiazide 25Mg Tablets	Box Of 20 Tablets
Cardiology - Medicines	770070103	Hydrochlorothiazide 50Mg + Amiloride 5Mg Tablets	Box Of 28 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	910010508	Hydrocortisone 100Mg Injection	Box Of 10 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	910080103	10Mg Tablets Hydrocortisone	Box Of 25 Tablets
Gastroenterology	610010101	Hydroxide Aluminum And De Magnesium Suspension Oral	Bottle 250Ml
Anesthesia - Resuscitation	300060501	Hydroxyzine 100Mg Injection	Box Of 6 Bulbs
Analgesics --Antipyretics --	DMP122	Ibuprofen 100Mg / 5Ml Syrup	Bottle 150Ml



Class Therapeutic	CODE	Name Common International	Packaging
Anti- Inflammatory			
Infectious disease	4052502505	Imipenem 250Mg + Cilastatin 250Mg Injection	Box Of 10 Bottles
Infectious disease	4055005005	Imipenem 500Mg + Cilastatin 500Mg Injection	Box 1 Bottle
Psychiatry - Neurology	DMP58	25Mg Tablets Imipramine	Box Of 100 Tablets
Cardiology - Medicines	78008001	Indapamide 1.5 Mg Tablets Lp	Box Of 30 Tablets
Cardiology - Medicines	78008002	Indapamide 2.5 Mg Tablets	Box Of 30 Tablets
Ophthalmology	1340051609	Indomethacin 0.1% Eye Drops	Box Of 10 Bottles
Analgesics --Antipyretics -- Anti- Inflammatory	1000014118	Indomethacin 100Mg Suppositories	Box Of 20 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000050103	Indomethacin 25Mg Capsules	Box Of 30 Capsules
Anesthesia - Resuscitation	100090201	Isoprenaline 0.2Mg Injection	Box Of 50 Bulbs
Infectious disease	405250105	Josamycin 250Mg Powder For Oral Susp	Box D1 'Bottle 60Ml
Infectious disease	405500105	Josamycin 500Mg Powder For Oral Susp	Box 1 Bottle 60Ml
Anesthesia - Resuscitation	400010101	Ketamine 10Mg / Ml Injection	Box Of 25 Bulbs
Anesthesia - Resuscitation	400050101	Ketamine 50Mg / Ml Injection	Box Of 25 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	1000100501	Ketoprofen 100Mg Injection	Box Of 60 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	1000200501	Ketoprofen 100Mg Tablet	Box Of 30 Tablets



Class Therapeutic	CODE	Name Common International	Packaging
Anesthesia - Resuscitation	300300301	Lactate De Sodium Chloride De Sodium Chloride De Potassium, Chloride De Calcium	Carton Of 12 Bottles 500ML
Gastroenterology	600500501	Lactulose 50% Oral Solution	Bottle 200ML
Metabolism --Hematology -- Diabetes --Nutrition	1800336501	Lenograstim 33.6 MIU Injection	Box 5 Bottles
Metabolism --Hematology -- Diabetes --Nutrition	1800340501	Lenograstim 34 MIUMIU Injection	Box 1 Bottle
Psychiatry - Neurology	1210100103	Levomepromazine 100Mg Tablet	Box Of 100 Tablets
Psychiatry - Neurology	1210120103	25Mg Tablets Levomepromazine	Box Of 100 Tablets
Psychiatry - Neurology	1210110301	Levomepromazine Injection 25Mg	Box 5 Bulbs
Metabolism --Hematology -- Diabetes --Nutrition	960030103	Levothyroxine Sodium 100 Micrograms Tablets Scored	Box Of 50 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	9600500103	Levothyroxine Sodium Tablets 50Mg	Box Of 28 Tablets
Anesthesia - Resuscitation	210060407	Lidocaine 1% Injection	Box Of 10 Bottles
Anesthesia - Resuscitation	210020607	Lidocaine 2% + Adrenaline Injection	Box Of 10 Bottles
Anesthesia - Resuscitation	210030607	Lidocaine 2% Injection	Box Of 10 Bottles
Anesthesia - Resuscitation	210040701	Lidocaine 5% + Naphazoline	Bottle 24ML
Anesthesia - Resuscitation	210040407	Lidocaine 5% Contact	Bottle 24ML
Psychiatry - Neurology	1270250103	Lithium 250Mg Tablet	Box Of 100



Class Therapeutic	CODE	Name Common International	Packaging
			Tablets
Psychiatry - Neurology	1270400103	Lithium 400Mg Tablet	Box Of 60 Tablets
Gastroenterology	6004002001	Loperamide 2Mg Capsule	Box Of 20 Capsules
Allergology	DMP123	10Mg Tablets Loratadine	Box Of 15 Tablets
Allergology	DMP124	Loratadine 5Mg / 5Ml Syrup	Bottle 60Ml
Cardiology - Medicines	730060503	50Mg Tablets Losartan	Box 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	DMP129	Magnesium Sulfate Injection	Box 5 Bulbs
Cardiology - Medicines	2220040407	10% Mannitol Injection	Box Of 12 Bottles 500Ml
Cardiology - Medicines	2220040807	20% Mannitol Injection	Pocket 500Ml
Anesthesia - Resuscitation	640200103	Mebeverine 200Mg Tablet	Box 30 Scored Tablets
Oncology --Hormone Therapy - -Immunology	1010050201	Melphalan 2Mg Tablet	Box Of 50 Tablets
Psychiatry - Neurology	1230050301	Meprobamate 400Mg Injection	Box Of 10 Bulbs
Allergology	300040006	Mequitazine 0.06 G / Syrup 120Ml	Bottle 120Ml
Gastroenterology	600600501	Mesalazine 1% Rectal Suspension	Box 5 Bottles
Gastroenterology	6006001003	Mesalazine 1G Suppositories	Box 15 Suppositories
Gastroenterology	6006050103	Mesalazine 500Mg Tablet	Box Of 100 Tablets
Oncology --Hormone Therapy -	1010060401	Mesna 400Mg Injection	Box Of 15 Bulbs



Class Therapeutic	CODE	Name Common International	Packaging
-Immunology			
Metabolism --Hematology -- Diabetes --Nutrition	9200510103	Metformin 1000Mg Tablets	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	DMP59	Metformin 500Mg Tablet	Box Of 50 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	920050103	Metformin 850Mg Tablets	Box Of 60 Tablets
Oncology --Hormone Therapy - -Immunology	1010070201	Methotrexate Injection 25Mg	Box 1 Bottle
Cardiology - Medicines	730020103	Methyldopa 250Mg Tablet	Box Of 30 Tablets
Gynecology - Obstetrics	1630010501	Methylergometrine 0.2Mg Injection	Box Of 50 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	910050201	Methylprednisolone 120Mg Injection	Box Of 10 Bottles
Analgesics --Antipyretics -- Anti- Inflammatory	910040201	Methylprednisolone Injection 40Mg	Box Of 10 Bottles
Analgesics --Antipyretics -- Anti- Inflammatory	910050501	Methylprednisolone 500Mg Injection	Box Of 10 Bottles
Gastroenterology	620020103	10Mg Tablets Metoclopramide	Box Of 500 Tablets
Gastroenterology	620010501	Metoclopramide Injection 10Mg	Box Of 50 Bulbs
Gastroenterology	620020502	Metoclopramide 20Mg Suppositories	Box 10 Suppositories
Gastroenterology	620030109	Metoclopramide 260Mg / Sol 100Ml Oral	Box 1 Flaconde 60Ml
Gastroenterology	620016503	Metoclopramide Delay 16Mg	Box Of 30



Class Therapeutic	CODE	Name Common International	Packaging
		Capsule	Capsules
Gastroenterology	620004504	Metopimazine 0.4% Oral Solution	Bottle 30MI
Gastroenterology	6007010501	Metopimazine 10Mg / Ml Injection	Box Of 10 Bulbs
Gastroenterology	6007050003	Metopimazine 5Mg Suppositories	Box 10 Suppositories
Infectious disease	440080103	Metronidazole 250Mg Tablet	Box Of 100 Tablets
Infectious disease	440070106	4% Metronidazole Syrup	Box Of 25 Bottles 120MI
Infectious disease	440280103	Metronidazole 500Mg Tablet	Box Of 100 Tablets
Infectious disease	DMP60	Metronidazole 500Mg Injection	Pocket 100MI
Gynecology - Obstetrics	440091514	Metronidazole 500Mg Ova	Box 50 Ova
Psychiatry - Neurology	220100201	Midazolam 5Mg / 5Ml Injection	Box Of 6 Bulbs 5MI
Anesthesia - Resuscitation	1010030709	Morphine 100Mg Tablets Lp	Box Of 14 Tablets
Anesthesia - Resuscitation	1010030701	10Mg Tablets Morphine Lp	Box Of 14 Tablets
Anesthesia - Resuscitation	1010030702	20Mg Tablets Morphine Lp	Box Of 14 Tablets
Anesthesia - Resuscitation	1010030703	30Mg Tablets Morphine Lp	Box Of 14 Tablets
Anesthesia - Resuscitation	1010030706	60Mg Tablets Morphine Lp	Box Of 14 Tablets



Class Therapeutic	CODE	Name Common International	Packaging
Anesthesia - Resuscitation	1010030601	Morphine Hydrochloride Injection 10Mg	Box 100 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	810020201	Nefopam Injection 20Mg	Box Of 15 Bulbs
Anesthesia - Resuscitation	100120201	Neostigmine 0.5Mg Injection	Box Of 60 Bulbs
Cardiology - Medicines	710080501	Nicardipine Injection 10Mg	Box Of 10 Bulbs
Cardiology - Medicines	710080105	Nicardipine 50Mg Capsules	Box Of 60 Capsules
Cardiology - Medicines	730060103	20Mg Tablet Nifedipine	Box Of 50 Tablets
Cardiology - Medicines	730060303	30Mg Tablets Nifedipine	Box Of 30 Tablets
Infectious disease	DMP64	Nifuroxazide 100Mg Capsule	Box Of 30 Capsules
Infectious disease	DMP65	Nifuroxazide 200Mg Capsule	Box Of 30 Capsules
Infectious disease	DMP66	Nifuroxazide Oral Suspension	Bottle 90ML
Infectious disease	455100103	Nitroxoline 100Mg Tablet	Box Of 50 Tablets
Infectious disease	4500100106	Nystatin 000Ui 100 / ML Oral Suspension	Bottle Of 24 Doses
Gastroenterology	6100410103	10Mg Capsule Omeprazole	Box Of 28 Capsules
Gastroenterology	610040103	20Mg Capsule Omeprazole	Box Of 28 Capsules
Gastroenterology	6100440501	Omeprazole Injection 40Mg	Box 5 Bottles
Gastroenterology	6008040005	Ondansetron 4Mg / 2ML Injection	Box 5 Bulbs



Class Therapeutic	CODE	Name Common International	Packaging
Ophthalmology	DMP68	Oxytetracycline + Dexamethasone Ointment Ophthalmic	Box 12 Unidoses
Gynecology - Obstetrics	1630020401	Oxytocin 5 IU Injection	Box 3 Bulbs
Anesthesia - Resuscitation	220010201	Pancuronium 4Mg Bromide Injection	Box Of 10 Bulbs
Analgesics --Antipyretics -- Anti- Inflammatory	DMP110	Paracetamol 100Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000021418	Paracetamol 125Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	DMP125	Paracetamol 150Mg Bags	Box 12 Packs
Analgesics --Antipyretics -- Anti- Inflammatory	DMP116	Paracetamol 150Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	100002170	Paracetamol 170Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	DMP126	Paracetamol 1G Injection	Box Of 12 Bottles
Analgesics --Antipyretics -- Anti- Inflammatory	1000090103	Paracetamol 1G Tablets	Box Of 10 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	DMP112	Paracetamol 200Mg Bags	Box 12 Packs
Analgesics --Antipyretics -- Anti- Inflammatory	DMP111	Paracetamol 200Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000031418	Paracetamol 250Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000010418	Paracetamol Syrup 3%	Bottle 90Ml



Class Therapeutic	CODE	Name Common International	Packaging
Analgesics --Antipyretics -- Anti- Inflammatory	DMP117	Paracetamol 300Mg Bags	Box 12 Packs
Analgesics --Antipyretics -- Anti- Inflammatory	DMP118	Paracetamol 300Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000035018	Paracetamol 350Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000062018	Paracetamol 400Mg + Codeine 20Mg Tablets	Box Of 16 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	1000063018	Paracetamol 400Mg + Dextropropoxyphene 30Mg Capsules	Box Of 18 Capsules
Analgesics --Antipyretics -- Anti- Inflammatory	1000070103	Paracetamol 500Mg Tablet	Box Of 100 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	1000070301	Paracetamol 500Mg Injection	Box Of 12 Bottles 50Ml
Analgesics --Antipyretics -- Anti- Inflammatory	1000057003	Paracetamol 500Mg Suppositories	Box 100 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	1000081418	Paracetamol 80Mg Suppositories	Box 100 Suppositories
Psychiatry - Neurology	1240050103	10Mg Tablets Phenobarbital	Box Of 80 Tablets
Psychiatry - Neurology	1240020501	Phenobarbital 200Mg Injection	Box 5 Bulbs
Psychiatry - Neurology	1240060801	Phenobarbital Injection 40Mg	Box Of 50 Bottles + Solvent
Psychiatry - Neurology	1240070103	50Mg Tablets Phenobarbital	Box Of 30 Tablets
Infectious disease	410310105	Phenoxymethylpenicillin 0.25 MIU / 5Ml Syrup	Box Of 25 Bottles 100Ml



Class Therapeutic	CODE	Name Common International	Packaging
Infectious disease	410300103	Phenoxymethylpenicillin 1 MIUMIU Tablets	Box Of 12 Tablets
Ophthalmology	DMP35	Phenylephrine 10% Eye Drops	Bottle 10MI
Anesthesia - Resuscitation	2220	Serum Glucose 10% Hypert 500 MI Pocket	Cardboard 12 Pockets 500MI
Anesthesia - Resuscitation	2220020407	Serum Glucose 15% 500 MI Bottle	Carton Of 12 Bottles 500MI
Anesthesia - Resuscitation	2220030407	Serum Glucose 30% 125 MI Bottle	Carton Of 12 Bottles 125MI
Anesthesia - Resuscitation	2220120407	Serum Glucose 5% 250 MI Bottle	Carton Of 12 Bottles 250MI
Anesthesia - Resuscitation	2220120407	Serum Glucose 5% 250 MI Pocket	Cardboard 12 Pockets 250MI
Cardiology - Medicines	790020103	Simvastatin 20Mg Tablets	Box Of 60 Tablets
Cardiology - Medicines	790040103	Simvastatin 40Mg Tablets	Box Of 60 Tablets
Anesthesia - Resuscitation	2220060407	Sodium Bicarbonate 1.4% 250 MI Bottle	Carton Of 12 Bottles 250MI
Anesthesia - Resuscitation	2220100407	Sodium Chloride 0.9% 500 MI Bottle	Carton Of 12 Bottles 500MI
Anesthesia - Resuscitation	2220100407	Sodium Chloride 0.9% 500 MI Pocket	Cardboard 12 Pockets 500MI
Anesthesia - Resuscitation	222018	Sodium Chloride Injection 10%	Box 100 Bulbs
Gynecology - Obstetrics	DMP75F	Solution Antiseptic To Application Local In Gynecology	Bottle 250MI



Class Therapeutic	CODE	Name Common International	Packaging
Anesthesia - Resuscitation	DMP121	Solution De Filling Vascular To Base De Gelatin Or Dextran Or	Pocket Or Bottle 500Ml
Infectious disease	410620105	Spiramycin 0.375 MIU Syrup	Bottle 150Ml
Infectious disease	DMP114	Spiramycin 0.75 MIU Tablets Or Bag	Box De 20 Tablets Or Bags
Infectious disease	410390103	Spiramycin 1.5 MIU + Metronidazole 250Mg Tablets	Box Of 15 Tablets
Infectious disease	DMP115	Spiramycin 1.5 MIU Tablets Or Bag	Box De 16 Tablets Or Bags
Infectious disease	4103000103	Spiramycin 3 MIU Tablets	Box Of 10 Tablets
Cardiology - Medicines	7700602501	Spironolactone 25Mg + Altizide 15Mg Tablets	Box Of 20 Tablets
Cardiology - Medicines	770060501	50Mg Tablets Spironolactone	Box Of 20 Tablets
Cardiology - Medicines	100140201	Streptokinase 1500 000Ui Injection	Box 1 Bottle
Anesthesia - Resuscitation	333030201	Sufentanil 250Mg Injection	Box Of 10 Bulbs
Anesthesia - Resuscitation	333010201	Sufentanil 50Mg Injection	Box 5 Bulbs
Dermatology	1980021701	Sulfadiazine Silver Cream 1%	Tube 50 G
Infectious disease	410130103	Sulfamethoxazole 100Mg + Trimethoprim 20Mg Tablet	Box Of 200 Tablets
Infectious disease	410140105	Sulfamethoxazole 4G + Trimethoprim 800Mg Suspension Oral	Carton Of 10 Bottles 100Ml



Class Therapeutic	CODE	Name Common International	Packaging
Infectious disease	410640103	Sulfamethoxazole 800Mg + Trimethoprim 160Mg Tablet	Box Of 20 Tablets
Infectious disease	410160103	Sulphametoxazole 400Mg + Trimethoprim 80Mg Tablet	Box Of 200 Tablets
Gastroenterology	DMP77	Sulfasalazine 500Mg Tablet	Box Of 100 Tablets
Products Contrast	2200020105	Barium Sulfate Sol. Oral Or Rectal	Bottle 150Ml
Dermatology	1890021202	Sulfate De Copper + Sulfate De Zinc + Oxide De Zinc + Camphor Ointment	Box Of 25 Tubes 20G
Metabolism --Hematology -- Diabetes --Nutrition	1133080103	Ferrous Sulphate 80Mg Tablets	Box Of 30 Tablets
Analgesics --Antipyretics -- Anti- Inflammatory	930020103	20Mg Tablets Or Capsules Tenoxicam	Box De 10 Tablets Or Capsules
Analgesics --Antipyretics -- Anti- Inflammatory	930020301	Tenoxicam 20Mg Suppositories	Box Of 6 Suppositories
Metabolism --Hematology -- Diabetes --Nutrition	DMP78	Tetracosactide 1Mg Injection	Box 1 Bulb
Infectious disease	410350103	Tetracycline 500Mg Tablet	Box Of 100 Tablets
Pneumology	DMP144	Theophylline 300Mg Tablets Lp	Box Of 30 Tablets
Metabolism --Hematology -- Diabetes --Nutrition	2100050103	Thiamine + Pyridoxine + Cyanocobalamin Tablets	Box Of 20 Tablets
Infectious disease	410360505	Thiamphenicol 750Mg	Box Of 8 Bottles



Class Therapeutic	CODE	Name Common International	Packaging
		Injection	+ Solvent
Infectious disease	DMP79	Thiamphenicol 125Mg Powder For Oral Susp	Bottle 60Ml
Infectious disease	410540103	Thiamphenicol 250Mg Tablet	Box Of 16 Tablets
Infectious disease	410500103	Thiamphenicol 500Mg Tablet	Box Of 16 Tablets
Anesthesia - Resuscitation	DMP145	Thiocolchicoside 4Mg Injection	Box Of 6 Bulbs
Anesthesia - Resuscitation	220070205	Thiopental 1G Sodium Injection	Box Of 50 Bottles
Anesthesia - Resuscitation	640101418	Tiemonium Simple 20Mg Suppositories	Box 100 Suppositories
Anesthesia - Resuscitation	640080501	Tiemonium Single Injection 5Mg	Box Of 10 Bulbs
Anesthesia - Resuscitation	640070101	Tiemonium Simple 10Mg / 5Ml Syrup	Bottle 150Ml
Ophthalmology	1320031609	Timolol 0.50% Eye Drops	Bottle 5Ml
Analgesics --Antipyretics -- Anti- Inflammatory	960010031	Tramadol 100Mg Suppositories	Box 5 Suppositories
Analgesics --Antipyretics -- Anti- Inflammatory	960050103	Tramadol 50Mg Tablets Or Capsules	Box De 20 Tablets Or Capsules
Psychiatry - Neurology	1250030103	Trihexyphenidyl 5Mg Tablet	Box Of 20 Tablets
Anesthesia - Resuscitation	710010103	Trimebutine Oral Suspension	Bottle 250Ml
Anesthesia - Resuscitation	710050101	Trimebutine 150Mg Tablet Or Capsule	Box De 30 Tablets Or



Class Therapeutic	CODE	Name Common International	Packaging
			Capsules
Cardiology - Medicines	790060201	Trimetazidine Dihydrochloride 20Mg Tablets	Box Of 60 Tablets
Cardiology - Medicines	DMP96	Nitroglycerin 0.3Mg / Spray Aerosol	Bottle 300 Doses
Cardiology - Medicines	710050501	Nitroglycerin Injection 15Mg	Box Of 50 Bulbs
Cardiology - Medicines	710050301	Nitroglycerin 3Mg Injection	Box Of 50 Bulbs
Cardiology - Medicines	DMP81	Nitroglycerin 6,5Mg Capsule	Box Of 60 Capsules
Ophthalmology	DMP82	Tropicamide 0.5% Eye Drops	Box Of 10 Bottles 10Ml
Psychiatry - Neurology	DMP83	Valproate Sodium Syrup	Bottle 150Ml
Psychiatry - Neurology	1240100103	Valproate Sodium Tablets 200Mg	Box Of 40 Tablets
Psychiatry - Neurology	1240090107	Valproate De Sodium 200Mg / Ml Solution Oral	Bottle 40Ml
Infectious disease	430500501	Vancomycin 500Mg Injection	Box 1 Bottle
Other	1890051202	White Vaseline	Pack Of 1 Kg
Anesthesia - Resuscitation	220080201	Vecuronium 4Mg Bromide Injection	Box Of 10 Bulbs
Oncology --Hormone Therapy - -Immunology	1010081001	Vincristine 1Mg Injection	Box 1 Bottle



6.4 Reimbursement of anti-cancer drugs (in MAD)

Table 14: Reimbursements of anti-cancer drugs

Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
AVASTIN	BEVACIZUMAB	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE	3,983.00	3,983.00	3,689.00	3,689.00
AVASTIN	BEVACIZUMAB	INFUSION AT 400 MG POWDER FOR SOLUTION	1 BOX 1 BOTTLE	13,417.00	13,417.00	13,161.00	13,161.00
BLUCIN	BLEOMYCINE	INJECTION 15 MG POWDER FOR SOLUTION	1 BOX 1 BOTTLE	215.00	215.00	134.40	134.40
BLEOMYCINE BELLON	BLEOMYCINE	INJECTION 15 MG	1 BOX 1 BOTTLE	345.00	215.00	229.00	134.40
XELODA	CAPECITABINE	FILM-COATED TABLETS 150 MG	1 BOX 60 TABLETS			559.70	559.70
XELODA	CAPECITABINE	FILM-COATED TABLETS 500 MG	1 BOX 120 TABLETS	3,696.00	3,696.00	3,393.00	3,393.00
CARBOPLATINE DBL	CARBOPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	272.00	272.00	181.00	181.00
CARBOPLATINE MYLAN	CARBOPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	272.00	272.00	181.00	181.00
CARBOPLATINE AGUETTANT 50 MG	CARBOPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	467.00	467.00	310.00	310.00
OKA-CARBOPLATIN	CARBOPLATINE	SOLUTION FOR INFUSION AT 150 MG	1 BOX 1 BOTTLE	572.00	572.00	380.00	380.00
CARBOPLATINE DBL	CARBOPLATINE	SOLUTION FOR INFUSION AT 150 MG	1 BOX 1 BOTTLE	663.00	663.00	441.00	441.00
CARBOPLATINE MYLAN	CARBOPLATINE	SOLUTION FOR INFUSION AT 150 MG	1 BOX 1 BOTTLE	684.00	684.00	454.00	454.00
CARBOPLATINE AGUETTANT 150 MG	CARBOPLATINE	SOLUTION FOR INFUSION AT 150 MG	1 BOX 1 BOTTLE	1,096.00	1,096.00	820.00	820.00
OKA-CARBOPLATIN	CARBOPLATINE	SOLUTION FOR INFUSION AT 450 MG	1 BOX 1 BOTTLE	1,175.00	1,175.00	900.00	900.00
CARBOPLATINE DBL	CARBOPLATINE	SOLUTION FOR INFUSION AT 450 MG	1 BOX 1 BOTTLE	1,493.00	1,493.00	1,228.00	1,228.00
CARBOPLATINE MYLAN	CARBOPLATINE	SOLUTION FOR INFUSION AT 450 MG	1 BOX 1 BOTTLE	1,577.00	1,577.00	1,315.00	1,315.00
CARBOPLATINE AGUETTANT 450 MG	CARBOPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	2,713.00	2,713.00	2,381.00	2,381.00
PARAPLATINE	CARBOPLATINE	SOLUTION FOR INFUSION AT 450 MG	1 BOTTLE 5 ML	835.30	835.30	552.50	552.50
CARBOPLATINE COOPER	CARBOPLATINE	SOLUTION FOR INFUSION AT 150 MG	1 BOTTLE 15 ML	686.00	686.00	456.00	456.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
PARAPLATINE	CARBOPLATINE	SOLUTION FOR INFUSION AT 150 MG	1 BOTTLE 15 ML	1,871.00	686.00	1,237.70	456.00
CARBOPLATINE COOPER	CARBOPLATINE	SOLUTION FOR INFUSION AT 450 MG	1 BOTTLE 45 ML	1,553.00	1,553.00	1,289.00	1,289.00
PARAPLATINE	CARBOPLATINE	SOLUTION FOR INFUSION AT 450 MG	1 BOTTLE 45 ML	5,586.80	1,553.00	3,695.70	1,289.00
ZAREX	CARBOPLATINE	POWDER FOR SOLUTION INJECTION 150 MG	1 BOX 1 BOTTLE	968.00	968.00	687.00	687.00
ZAREX	CARBOPLATINE	POWDER FOR SOLUTION INJECTION 450 MG	1 BOX 1 BOTTLE	2,289.00	2,289.00	1,944.00	1,944.00
SANDIMMUN	CICLOSPORINE	SOLUTION FOR INFUSION AT 50 MG	10 AMPULE 1 ML			327.80	327.80
SANDIMMUN	CICLOSPORINE	SOLUTION FOR INFUSION AT 50 MG	10 AMPULE 5 ML			1,820.40	1,820.40
SANDIMMUN	CICLOSPORINE	ORAL SOLUTION 100 MG	1 BOTTLE 10 ML			550.40	550.40
NEORAL	CICLOSPORINE	ORAL SOLUTION 100 MG	1 BOTTLE 20 ML			931.30	931.30
EQUORAL	CICLOSPORINE	ORAL SOLUTION 100 MG	1 BOTTLE 50 ML	1,736.00	1,736.00	1,452.00	1,452.00
NEORAL	CICLOSPORINE	ORAL SOLUTION 100 MG	1 BOTTLE 50 ML	1,736.00	1,736.00	1,452.00	1,452.00
SANDIMMUN	CICLOSPORINE	ORAL SOLUTION 100 MG	1 BOTTLE 50 ML	1,755.00	1,736.00	1,472.00	1,452.00
EQUORAL	CICLOSPORINE	CAPSULES 25 MG	1 BOX 30 CAPSULE	338.00	338.00	224.00	224.00
EQUORAL	CICLOSPORINE	CAPSULES 50 MG	1 BOX 30 CAPSULE	699.00	699.00	463.00	463.00
EQUORAL	CICLOSPORINE	CAPSULES 100 MG	1 BOX 30 CAPSULE	1,110.00	1,110.00	810.00	810.00
IMUSPORIN	CICLOSPORINE	CAPSULES 25 MG	1 BOX 50 CAPSULE MOLLE	544.00	544.00	360.00	360.00
IMUSPORIN	CICLOSPORINE	CAPSULES 50 MG	1 BOX 50 CAPSULE MOLLE	1,063.00	1,063.00	762.00	762.00
IMUSPORIN	CICLOSPORINE	CAPSULES 100 MG	1 BOX 50 CAPSULE MOLLE	1,691.00	1,691.00	1,406.00	1,406.00
EQUORAL	CICLOSPORINE	CAPSULES 25 MG	1 BOX 50 CAPSULE	544.00	544.00	360.00	360.00
SANDIMMUN	CICLOSPORINE	CAPSULES 25 MG	1 BOX 50 CAPSULE	565.00	544.00	374.00	360.00
EQUORAL	CICLOSPORINE	CAPSULES 50 MG	1 BOX 50 CAPSULE	1,063.00	1,063.00	762.00	762.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
SANDIMMUN	CICLOSPORINE	CAPSULES 50 MG	1 BOX 50 CAPSULE	1,123.00	1,063.00	823.00	762.00
EQUORAL	CICLOSPORINE	CAPSULES 100 MG	1 BOX 50 CAPSULE	1,638.00	1,638.00	1,351.00	1,351.00
SANDIMMUN	CICLOSPORINE	CAPSULES 100 MG	1 BOX 50 CAPSULE	1,746.00	1,691.00	1,463.00	1,406.00
NEORAL	CICLOSPORINE	CAPSULES 25 MG	1 BOX 60 CAPSULE	653.00	653.00	432.00	432.00
NEORAL	CICLOSPORINE	CAPSULES 50 MG	1 BOX 60 CAPSULE	1,213.00	1,213.00	915.00	915.00
NEORAL	CICLOSPORINE	CAPSULES 100 MG	1 BOX 60 CAPSULE	1,966.00	1,966.00	1,688.00	1,688.00
CEPLATIN	CISPLATINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	37.80	37.80	23.60	23.60
CISPLATINE EBWE	CISPLATINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	43.00	43.00	26.90	26.90
CISPLATINE COOPER	CISPLATINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	45.00	45.00	28.10	28.10
CISPLATINE MYLAN	CISPLATINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	51.40	51.40	32.10	32.10
PLATAMINE	CISPLATINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	67.70	51.40	42.30	32.10
CISPLATINE MYLAN	CISPLATINE	SOLUTION FOR INFUSION AT 25 MG	1 BOX 1 BOTTLE	80.10	80.10	50.10	50.10
CEPLATIN	CISPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	117.90	117.90	73.70	73.70
CISPLATINE EBWE	CISPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	133.00	133.00	83.10	83.10
CISPLATINE COOPER	CISPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	140.00	140.00	87.50	87.50
CISPLATINE MYLAN	CISPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	154.20	154.20	96.40	96.40
PLATAMINE	CISPLATINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	197.70	154.20	123.60	96.40
CYCLOMIDE NOVOPHARMA 1000 MG	CYCLOPHOSPHAMIDE	POWDER FOR PARAENTERAL USE À 1 G	1 BOX 1 BOTTLE	51.00	51.00	31.90	31.90
ENDOXAN 1 G	CYCLOPHOSPHAMIDE	INJECTABLE IV À 1 G	1 BOX 1 BOTTLE	89.40	51.00	55.90	31.90
CYCLOMIDE NOVOPHARMA 500 MG	CYCLOPHOSPHAMIDE	POWDER FOR PARAENTERAL USE À 500 MG	1 BOX 1 BOTTLE	34.20	34.20	21.40	21.40
ENDOXAN 500 MG	CYCLOPHOSPHAMIDE	POWDER FOR SOLUTION INJECTABLE IV À 500 MG	1 BOX 1 BOTTLE	56.10	34.20	35.10	21.40



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
ENDOXAN 200 MG	CYCLOPHOSPHAMIDE	POWDER FOR SOLUTION INJECTABLE IV À 500 MG	1 BOX 10 BOTTLE	184.30	184.30	115.20	115.20
ENDOXAN 50 MG	CYCLOPHOSPHAMIDE	COATED TABLETS 50 MG	2 BOX 50 TABLETS	87.20	87.20	54.50	54.50
ANDROCUR	CYPROTERONE	COATED TABLETS 50 MG	1 BOX 20 TABLETS	201.00	201.00	125.70	125.70
CYTARABINE EBEWE	CYTARABINE	SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 5 ML	42.00	42.00	26.20	26.20
CYTARABINE EBEWE	CYTARABINE	SOLUTION FOR INFUSION AT 500 MG	1 BOTTLE 10 ML	195.00	195.00	121.90	121.90
ARACYTINE	CYTARABINE	POWDER FOR SOLUTION INJECTION 1 G	1 BOTTLE 5 ML	436.00	436.00	290.00	290.00
ARACYTINE	CYTARABINE	POWDER FOR SOLUTION INJECTION 100 MG	1 BOX 1 AMPULE INJECTION	54.40	54.40	34.00	34.00
ARACYTINE	CYTARABINE	POWDER FOR SOLUTION INJECTION 500 MG	1 BOTTLE 5 ML	232.00	232.00	145.40	145.40
D-BLASTIN	DAUNORUBICINE	POWDER FOR INFUSION AT 20 MG	1 BOX 1 BOTTLE	126.00	126.00	78.70	78.70
CERUBIDINE	DAUNORUBICINE	POWDER FOR INFUSION AT 20 MG	1 BOX 10 BOTTLE	1,050.00	1,050.00	772.00	772.00
DOCEWIN 20 MG/0.5 ML	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 0,5 ML	800.00	800.00	532.00	532.00
DOCETAXEL COOPER 21	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 0,5 ML	842.00	842.00	560.00	560.00
OKA-DOCETAXEL	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 0,5 ML	922.00	922.00	640.00	640.00
LEXUS	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 0,5 ML	1,348.00	1,348.00	1,079.00	1,079.00
TAXOTERE 20 MG/0.5 ML	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 0,5 ML	1,348.00	1,348.00	1,079.00	1,079.00
DOCETAXEL HOSPIRA 11 MG/ML	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 2 ML	804.00	804.00	531.80	531.80
DOCEWIN 80 MG/2 ML	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 80 MG	1 BOTTLE 2 ML	2,467.00	2,467.00	2,128.00	2,128.00
DOCETAXEL COOPER 80 MG	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 80 MG	1 BOTTLE 2 ML	2,575.00	2,575.00	2,239.00	2,239.00
OKA-DOCETAXEL	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 80 MG	1 BOTTLE 2 ML	2,877.00	2,877.00	2,550.00	2,550.00
LEXUS	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 80 MG	1 BOTTLE 2 ML	3,177.00	3,177.00	2,858.00	2,858.00
TAXOTERE 80 MG/2 ML	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 80 MG	1 BOTTLE 2 ML	3,177.00	3,177.00	2,858.00	2,858.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
DOCETAXEL HOSPIRA 10	DOCETAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 80 MG	1 BOTTLE 8 ML	2,572.00	2,572.00	1,701.40	1,701.40
DOXORUBICINE EBWE	DOXORUBICINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	74.00	74.00	46.20	46.20
D-RUBICIN-10	DOXORUBICINE	SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	95.30	95.30	59.60	59.60
ADRIPLASTINE	DOXORUBICINE	LYOPHILASATE FOR INFUSION 10 MG	1 BOX 1 BOTTLE	109.50	95.30	68.40	59.60
DOXORUBICINE EBWE	DOXORUBICINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	313.00	313.00	208.00	208.00
D-RUBICIN-50	DOXORUBICINE	SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	412.00	412.00	273.00	273.00
ADRIPLASTINE RD	DOXORUBICINE	LYOPHILASATE FOR INFUSION 50 MG	1 BOX 1 BOTTLE	454.00	412.00	302.00	273.00
DOXORUBICINE COOPER	DOXORUBICINE	LYOPHILASATE FOR INFUSION 50 MG	1 BOTTLE 10 ML	93.00	93.00	58.10	58.10
DOXORUBICINE COOPER	DOXORUBICINE	LYOPHILASATE FOR INFUSION 10 MG	1 BOTTLE 50 ML	429.00	429.00	285.00	285.00
OKARUBICIN	DOXORUBICINE	LYOPHILASATE FOR INFUSION INJECTION 10 MG	1 BOX 1 BOTTLE	90.00	90.00	56.20	56.20
OKARUBICIN	DOXORUBICINE	LYOPHILASATE FOR INFUSION INJECTION 50 MG	1 BOX 1 BOTTLE	407.00	407.00	270.00	270.00
EPIRUBICINE MYLAN 2 MG/ML	EPIRUBICINE	SOLUTION FOR INFUSION AT 10 / 5 MG/ML	1 BOX 1 BOTTLE	74.40	74.40	46.50	46.50
FARMORUBICINE	EPIRUBICINE	POWDER FOR INFUSION AT 10 / 5 MG/ML	1 BOX 1 BOTTLE	110.10	74.40	68.80	46.50
EPIRUBICINE MYLAN 2 MG/ML	EPIRUBICINE	SOLUTION FOR INFUSION AT 50 / 25 MG/ML	1 BOX 1 BOTTLE	325.00	325.00	216.00	216.00
FARMORUBICINE	EPIRUBICINE	POWDER FOR INFUSION AT 50 / 25 MG/ML	1 BOX 1 BOTTLE	495.00	325.00	329.00	216.00
ESTRACYT	ESTRAMUSTINE	CAPSULE 140 MG	1 BOX 100 CAPSULE	1,471.00	1,471.00	1,206.00	1,206.00
ETOPOSIDE COOPER	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE	118.00	118.00	73.70	73.70
OKA-ETOPOSIDE	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE	126.00	126.00	78.70	78.70
ETOPOPHOS	ETOPOSIDE	POWDER FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE	494.10	126.00	326.80	78.70
ETOPOSIDE COOPER	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOX 5 BOTTLE	529.00	529.00	352.00	352.00
VEPESIDE	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOX 5 BOTTLE			874.70	352.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
ETOPOSIDE EBWE	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 5 ML	118.00	118.00	73.70	73.70
ETOPOSIDE MYLAN	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	10 BOTTLE 5 ML	1,013.00	1,013.00	734.00	734.00
ETOPOSIDE MYLAN	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	10 BOTTLE 10 ML	1,465.00	1,465.00	1,200.00	1,200.00
ETOPOSIDE EBWE	ETOPOSIDE	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOTTLE 2,5 ML	62.00	62.00	38.70	38.70
ETOPOSIDE COOPER	ETOPOSIDE	CAPSULE À 50 MG	1 BOX 4 CAPSULE			190.00	190.00
ETOPOSIDE COOPER	ETOPOSIDE	CAPSULE À 50 MG	1 BOX 10 CAPSULE			425.00	425.00
AROMASINE	EXEMESTANE	COATED TABLETS 25 MG	1 BOX 30 TABLETS	969.00	969.00	689.00	689.00
FLUDARA	FLUDARABINE	FILM-COATED TABLETS 10 MG	1 BOX 15 TABLETS	3,606.00	3,606.00	3,301.00	3,301.00
FLUDARA	FLUDARABINE	FILM-COATED TABLETS 10 MG	1 BOX 20 TABLETS	4,940.00	4,940.00	4,673.00	4,673.00
FLUOROURACILE MYLAN	FLUOROURACIL	SOLUTION FOR INFUSION AT 250 MG	1 BOX 1 BOTTLE	13.90	13.90	9.20	9.20
FLUOROURACILE EBWE	FLUOROURACIL	SOLUTION FOR INFUSION AT 250 MG	INJECTION	69.00	69.00	43.10	43.10
FLUROURACILE ICN	FLUOROURACIL	SOLUTION FOR INFUSION AT 250 MG	1 BOX 12 VIALS	257.00	257.00	161.00	161.00
PHARMAURACIL 250MG/10ML	FLUOROURACIL	SOLUTION INJECTION 250 MG	1 BOX 1 BOTTLE	16.60	16.60	10.40	10.40
PHARMAURACIL	FLUOROURACIL	SOLUTION INJECTION 500 MG	1 BOTTLE 20 ML	25.00	25.00	16.50	16.50
ANDRAXAN	FLUTAMIDE	COATED TABLETS 250 MG	1 BOX 30 TABLETS ENROBE	250.00	250.00	156.20	156.20
EULEXINE	FLUTAMIDE	TABLETS 250 MG	1 BOX 30 TABLETS	283.00	283.00	188.40	188.40
FLUTAM	FLUTAMIDE	TABLETS 250 MG	1 BOX 30 TABLETS	283.00	283.00	188.40	188.40
LEDERFOLINE	FOLINATE DE CALCIUM	SOLUTION INJECTION 5 MG	1 BOX 1 AMPULE	17.70	17.70	11.70	11.70
LEDERFOLINE	FOLINATE DE CALCIUM	TABLETS 25 MG	1 BOX 6 TABLETS	104.50	104.50	65.10	65.10
LEDERFOLINE	FOLINATE DE CALCIUM	TABLETS 15 MG	1 BOX 10 TABLETS	109.20	109.20	68.00	68.00
LEDERFOLINE	FOLINATE DE CALCIUM	TABLETS 5 MG	1 BOX 20 TABLETS	97.60	97.60	60.80	60.80



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
ELVORINE	FOLINATE DE CALCIUM	PREPARATION INJECTION 25 MG	1 BOX 1 BOTTLE	52.00	52.00	32.40	32.40
ELVORINE	FOLINATE DE CALCIUM	PREPARATION INJECTION 50 MG	1 BOX 1 BOTTLE	100.00	100.00	62.30	62.30
FOLINATE DE CALCIUM AGUETTANT 100 MG	FOLINATE DE CALCIUM	POWDER FOR SOLUTION INJECTION 100 MG	1 BOX 1 BOTTLE	115.00	115.00	71.60	71.60
ELVORINE	FOLINATE DE CALCIUM	POWDER FOR SOLUTION INJECTION 100 MG	1 BOX 1 BOTTLE	195.00	115.00	121.50	71.60
ELVORINE	FOLINATE DE CALCIUM	PREPARATION INJECTION 175 MG	1 BOX 1 BOTTLE	338.00	338.00	224.00	224.00
FOLINATE DE CALCIUM AGUETTANT 50 MG	FOLINATE DE CALCIUM	PREPARATION INJECTION 50 MG	1 BOX 10 BOTTLE	677.00	677.00	448.00	448.00
LEDERFOLINE	FOLINATE DE CALCIUM	TABLETS 25 MG	1 BOX 6 TABLETS	104.50	104.50	65.10	65.10
LEDERFOLINE	FOLINATE DE CALCIUM	TABLETS 15 MG	1 BOX 10 TABLETS	109.20	109.20	68.00	68.00
LEDERFOLINE	FOLINATE DE CALCIUM	TABLETS 5 MG	1 BOX 20 TABLETS	97.60	97.60	60.80	60.80
CITAFINE 1G	MODIFIEE GEMCITABINE	POWDER FOR SOLUTION FOR INFUSION AT 1 G	1 BOTTLE 50 ML	971.00	971.00	691.00	691.00
GEMCITABINE HOSPIRA 1 G	GEMCITABINE	POWDER FOR SOLUTION FOR INFUSION AT 1 G	1 BOTTLE 50 ML	971.00	971.00	691.00	691.00
ONGECIN	GEMCITABINE	POWDER FOR SOLUTION FOR INFUSION AT 1 G	1 BOTTLE 50 ML	971.00	971.00	691.00	691.00
GEMZAR	GEMCITABINE	POWDER FOR INFUSION AT 1 G	1 BOTTLE 50 ML	1,200.00	971.00	927.00	691.00
GEMCITABINE HOSPIRA 200 MG	GEMCITABINE	POWDER FOR SOLUTION FOR INFUSION AT 200 MG	1 BOTTLE 10 ML	257.00	257.00	161.20	161.20
ONGECIN	GEMCITABINE	POWDER FOR SOLUTION FOR INFUSION AT 200 MG	1 BOTTLE 10 ML	257.00	257.00	161.20	161.20
GEMZAR	GEMCITABINE	POWDER FOR SOLUTION FOR INFUSION AT 200 MG	1 BOTTLE 10 ML	369.00	257.00	245.00	161.20
ZOLADEX 10.8 MG	GOSERELINE	IMPLANT INJECTION 10.8 MG	1 KIT 1 IMPLANT	3,340.00	3,340.00	3,026.00	3,026.00
ZOLADEX 3.6 MG	GOSERELINE	IMPLANT INJECTION 3.6 MG	1 BOX 1 SYRINGE	1,346.00	1,346.00	1,077.00	1,077.00
HYDREA	HYDROXYCARBAMIDE	CAPSULE 500 MG	1 BOX 20 CAPSULE	66.20	66.20	41.40	41.40
ZAVEDOS	IDARUBICINE	POWDER FOR SOLUTION FOR INFUSION AT 5 MG	1 BOTTLE 1 ML	994.00	994.00	715.00	715.00
ZAVEDOS	IDARUBICINE	POWDER FOR SOLUTION FOR INFUSION AT 10 MG	1 BOTTLE 1 ML	1,320.00	1,320.00	1,050.00	1,050.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
HOLOXAN	IFOSFAMIDE	POWDER FOR INFUSION AT 1 G	1 BOX 1 BOTTLE	409.00	409.00	272.00	272.00
HOLOXAN	IFOSFAMIDE	POWDER FOR INFUSION AT 2 G	1 BOX 1 BOTTLE	826.00	826.00	549.00	549.00
HOLOXAN	IFOSFAMIDE	POWDER FOR INFUSION AT 500 MG	1 BOX 1 BOTTLE	258.00	258.00	161.20	161.20
GLIVEC	IMATINIB	FILM-COATED TABLETS 100 MG	1 BOX 60 TABLETS PELLICULE	11,940.00	3,800.00	11,714.00	3,500.00
IMATEC	IMATINIB	CAPSULE 100 MG	1 BOX 120 CAPSULE	3,800.00	3,800.00	3,500.00	3,500.00
IMATINIB COOPER	IMATINIB	CAPSULE 100 MG	1 BOX 120 CAPSULE	3,800.00	3,800.00	3,500.00	3,500.00
GLIVEC	IMATINIB	CAPSULE 100 MG	1 BOX 120 CAPSULE	20,399.00	3,800.00	20,007.00	3,500.00
REMICADE	INFLIXIMAB		1 BOTTLE 20 ML	6,340.00	6,340.00	6,067.00	6,067.00
TECAN	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE	1,313.00	1,313.00	1,043.00	1,043.00
IRINOTECAN COOPER	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 40 MG	1 BOTTLE 2 ML	506.00	506.00	336.00	336.00
CAMPTO	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 40 MG	1 BOTTLE 2 ML	533.00	533.00	354.00	354.00
IRINOCYT 40 MG/2ML	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 40 MG	1 BOTTLE 2 ML	533.00	533.00	354.00	354.00
IRINOTECAN COOPER	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 5 ML	1,096.00	1,096.00	819.00	819.00
CAMPTO	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 5 ML	1,313.00	1,313.00	1,043.00	1,043.00
IRINOCYT 100 MG/5ML	IRINOTECAN	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 5 ML	1,313.00	1,313.00	1,043.00	1,043.00
TYKERB	LAPATINIB	TABLETS 250 MG	1 BOX 70 TABLETS	11,182.00	11,182.00	10,971.00	10,971.00
ARAVA	LEFLUNOMIDE	FILM-COATED TABLETS 100 MG	1 BOX 3 TABLETS	365.00	365.00	242.00	242.00
ARAVA	LEFLUNOMIDE	FILM-COATED TABLETS 10 MG	1 BOX 30 TABLETS	556.00	556.00	368.00	368.00
ARAVA	LEFLUNOMIDE	FILM-COATED TABLETS 20 MG	1 BOX 30 TABLETS	721.00	721.00	477.00	477.00
FEMARA	LETROZOLE	FILM-COATED TABLETS 2.5 MG	1 BOX 30 TABLETS PELLICULE	1,021.00	713.00	742.00	474.00
LETROZOLE GT	LETROZOLE	TABLETS 2.5 MG	1 BOX 30 TABLETS SECABLE	713.00	713.00	474.00	474.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
LETROZOL GT	LETROZOLE	TABLETS 2.5 MG	1 BOX 60 TABLETS SECABLE	1,110.00	1,110.00	834.00	834.00
ALKERAN 2 MG	MELPHALAN	FILM-COATED TABLETS 2 MG	1 BOX 50 TABLETS PELLICULE	100.40	100.40	62.70	62.70
PURINETHOL	MERCAPTOPYRINE	TABLETS 50 MG	1 BOX 25 TABLETS	47.50	47.50	29.70	29.70
PENTASA	MESALAZINE	TABLETS 500 MG	1 BOX 100 TABLETS	587.00	587.00	389.00	389.00
PENTASA	MESALAZINE	RECTAL SUSPENSION 1 G	5 BOTTLE 100 ML	256.00	256.00	159.80	159.80
PENTASA	MESALAZINE	SUPPOSITORY 1 G	1 BOX 15 SUPPOSITORY	337.00	337.00	223.00	223.00
UROMITEXAN	MESNA	SOLUTION FOR INFUSION AT 400 MG	15 AMPULE 4 ML	339.00	339.00	224.00	224.00
LEDERTREXATE	METHOTREXATE	POWDER FOR SOLUTION INJECTION 1 G	1 BOX 1 BOTTLE	492.50	492.50	325.60	325.60
METHOTREXATE MYLAN 100MG/ML	METHOTREXATE	INJECTION 5 G	10 BOTTLE 50 ML	11,067.00	11,067.00	10,858.00	10,858.00
METHOTREXATE MYLAN	METHOTREXATE	INJECTION 5 G	1 BOTTLE 200 ML	1,392.00	1,392.00	1,124.00	1,124.00
LEDERTREXATE	METHOTREXATE	INJECTION 5 G	1 BOTTLE 200 ML	2,491.30	1,392.00	1,648.00	1,124.00
METHOTREXATE BELLON	METHOTREXATE	INJECTION 25 MG	1 BOTTLE 1 ML	36.30	36.30	22.70	22.70
METHOTREXATE BIODIM	METHOTREXATE	INJECTION 25 MG	1 BOTTLE 1 ML	47.10	47.10	29.40	29.40
METHOTREXATE BELLON	METHOTREXATE	INJECTION 5 MG	1 BOTTLE 2 ML	21.20	21.20	13.20	13.20
METHOTREXATE BIODIM	METHOTREXATE	INJECTION 5 MG	1 BOTTLE 2 ML	30.70	30.70	19.20	19.20
LEDERTREXATE 50 MG	METHOTREXATE	INJECTION 50 MG	1 BOTTLE 2 ML	81.90	81.90	51.20	51.20
METHOTREXATE MYLAN	METHOTREXATE	INJECTION 5 MG	10 BOTTLE 2 ML	178.00	178.00	111.20	111.20
METHOTREXATE MYLAN 50 MG/2 ML	METHOTREXATE	INJECTION 50 MG	10 BOTTLE 2 ML	486.00	486.00	323.00	323.00
METHOTREXATE MYLAN	METHOTREXATE	INJECTION 500 MG	10 BOTTLE 20 ML	1,340.00	1,340.00	1,071.00	1,071.00
METHOTREXATE BELLON (H)	METHOTREXATE	INJECTION 500 MG	10 BOTTLE 20 ML	2,465.60	1,340.00	1,631.00	1,071.00
MITOXANTRONE EBWE	MITOXANTRONE	CONCENTRATION OF SOLUTION FOR INFUSION AT 10 MG	1 BOX 1 BOTTLE	1,199.00	1,199.00	926.00	926.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
MITOXANTRONE EBWE	MITOXANTRONE	CONCENTRATION OF SOLUTION FOR INFUSION AT 20 MG	1 BOX 1 BOTTLE	2,099.00	2,099.00	1,852.00	1,852.00
NOVANTRONE	MITOXANTRONE	SOLUTION FOR INFUSION AT 10 MG	1 AMPULE 5 ML	2,247.30	2,247.30	1,486.60	1,486.60
NOVANTRONE	MITOXANTRONE	SOLUTION FOR INFUSION AT 20 MG	1 AMPULE 10 ML	4,167.40	4,167.40	2,756.70	2,756.70
NOVANTRONE	MITOXANTRONE	SOLUTION FOR INFUSION AT 25 MG	1 AMPULE 12,5 ML	4,948.70	4,948.70	3,273.60	3,273.60
CELLCEPT	MYCOPHENOLATE MOFETIL	FILM-COATED TABLETS 500 MG	1 BOX 50 TABLETS	1,203.00	1,203.00	905.00	905.00
CELLCEPT	MYCOPHENOLATE MOFETIL	CAPSULE 250 MG	1 BOX 100 CAPSULE	1,203.00	1,203.00	905.00	905.00
ELOXATINE 5 MG/ML	OXALIPLATINE	POWDER FOR SOLUTION FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE 10 ML	1,203.00	1,203.00	929.00	929.00
ELOXATINE 5 MG/ML	OXALIPLATINE	POWDER FOR SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE 20 ML	2,206.00	2,206.00	1,859.00	1,859.00
ELOXATINE 5 MG/ML	OXALIPLATINE	CONCENTRATION OF SOLUTION FOR INFUSION AT 200 MG	1 BOX 1 BOTTLE 40 ML	2,882.00	2,882.00	2,555.00	2,555.00
OLIPLAT	OXALIPLATINE	POWDER FOR INFUSION AT 50 MG	1 BOX 1 BOTTLE	1,203.00	1,203.00	929.00	929.00
OLIPLAT	OXALIPLATINE	POWDER FOR SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE	2,206.00	2,206.00	1,859.00	1,859.00
OXALISIN 5 MG/ML	OXALIPLATINE	CONCENTRATION OF SOLUTION FOR INFUSION AT 50 MG	1 BOTTLE 10 ML	1,089.00	1,089.00	812.00	812.00
XYLATIN 50	OXALIPLATINE	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 10 ML	1,089.00	1,089.00	812.00	812.00
OXALISIN 5 MG/ML	OXALIPLATINE	CONCENTRATION OF SOLUTION FOR INFUSION AT 50 MG	1 BOTTLE 20 ML	1,864.00	1,864.00	1,610.00	1,610.00
XYLATIN 100	OXALIPLATINE	POWDER FOR SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 20 ML	1,869.00	1,869.00	1,615.00	1,615.00
OXAPLATINE MYLAN 5 MG/ML	OXALIPLATINE	POWDER FOR INFUSION AT 50 MG	1 BOTTLE 30 ML	1,203.00	1,203.00	929.00	929.00
OXALIPLATINE WIN 5 MG/ML	OXALIPLATINE	POWDER FOR INFUSION AT 50 MG	1 BOTTLE 36 ML	1,049.00	1,049.00	771.00	771.00
ELOXATINE 5 MG/ML	OXALIPLATINE	POWDER FOR INFUSION AT 50 MG	1 BOTTLE 36 ML	1,203.00	1,049.00	929.00	771.00
OXALIPLATINE WIN 5 MG/ML	OXALIPLATINE	POWDER FOR INFUSION AT 100 MG	1 BOTTLE 50 ML	1,468.00	1,468.00	1,203.00	1,203.00
ELOXATINE 5 MG/ML	OXALIPLATINE	POWDER FOR INFUSION AT 100 MG	1 BOTTLE 50 ML	2,206.00	2,206.00	1,859.00	1,859.00
OXAPLATINE MYLAN 5 MG/ML	OXALIPLATINE	POWDER FOR INFUSION AT 100 MG	1 BOTTLE 50 ML	2,206.00	2,206.00	1,859.00	1,859.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
SYNTOCINON	OXYTOCINE	INJECTION 5 UI	3 AMPULE 1 ML	17.20	17.20	10.70	10.70
ACUPAXIL-30	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	430.00	430.00	285.00	285.00
PACLITAXEL MYLAN PHARMA 30 MG/5ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	430.00	430.00	285.00	285.00
PACLITAXEL PHARMACHEMIE 6MG/ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	430.00	430.00	285.00	285.00
PACLITAXEL COOPER	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	452.00	452.00	300.00	300.00
OKA-PACLITAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	527.00	527.00	350.00	350.00
EBETAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	590.00	590.00	392.00	392.00
ANZATAX	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	619.00	619.00	411.00	411.00
PAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	619.00	619.00	411.00	411.00
TAXOL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 30 MG	1 BOTTLE 5 ML	619.00	619.00	411.00	411.00
OKA-PACLITAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 20 ML	1,271.00	1,271.00	1,000.00	1,000.00
PACLITAXEL PHARMACHEMIE 6MG/ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 150 MG	1 BOTTLE 25 ML	1,341.00	1,341.00	1,071.00	1,071.00
EBETAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 150 MG	1 BOTTLE 25 ML	2,317.00	2,317.00	1,973.00	1,973.00
ANZATAX	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 150 MG	1 BOTTLE 25 ML	2,476.00	2,476.00	2,137.00	2,137.00
PACLITAXEL MYLAN PHARMA 300 MG/50 ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 300 MG	1 BOTTLE 50 ML	1,574.00	1,574.00	1,312.00	1,312.00
PACLITAXEL PHARMACHEMIE 6MG/ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 300 MG	1 BOTTLE 50 ML	2,069.00	2,069.00	1,821.00	1,821.00
EBETAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 300 MG	1 BOTTLE 50 ML	4,043.00	4,043.00	3,750.00	3,750.00
PACLITAXEL MYLAN PHARMA 100 MG/16,7 ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 16,7 ML	823.00	823.00	547.00	547.00
PACLITAXEL PHARMACHEMIE 6MG/ML	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 16,7 ML	823.00	823.00	547.00	547.00
PACLITAXEL COOPER	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 16,7 ML	1,115.00	1,115.00	839.00	839.00
EBETAXEL	PACLITAXEL	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	1 BOTTLE 16,7 ML	1,563.00	1,563.00	1,300.00	1,300.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
ALIMTA	PEMETREXED	POWDER FOR SOLUTION FOR INFUSION AT 100 MG	1 BOX 1 BOTTLE			2,974.00	2,650.00
ALIMTA	PEMETREXED	POWDER FOR SOLUTION FOR INFUSION AT 500 MG	1 BOX 1 BOTTLE			11,999.00	11,771.00
TOMUDEX	RALTITREXED	POWDER FOR INFUSION AT 2 MG	1 BOX 1 BOTTLE			1,715.00	1,456.00
MABTHERA	RITUXIMAB	CONCENTRATION OF SOLUTION FOR INFUSION AT 100 MG	2 BOTTLE 10 ML	5,842.00	5,842.00	5,602.00	5,602.00
MABTHERA	RITUXIMAB	CONCENTRATION OF SOLUTION FOR INFUSION AT 500 MG	1 BOTTLE 50 ML	13,737.00	13,737.00	13,475.00	13,475.00
NEXAVAR	SORAFENIB	FILM-COATED TABLETS 200 MG	1 BOX 60 TABLETS	21,152.00	21,152.00	20,745.00	20,745.00
SALAZOPYRIN	SULFASALAZINE			141.70	141.70	88.30	88.30
PROGRAF	TACROLIMUS	CAPSULE 1 MG	1 BOX 100 CAPSULE	1,980.00	1,980.00	1,703.00	1,703.00
TAFEN	TAMOXIFENE	TABLETS 10 MG	1 BOX 20 TABLETS	50.00	50.00		
TAMOXIFENE MYLAN	TAMOXIFENE	TABLETS 10 MG	1 BOX 30 TABLETS	78.60	78.60	49.10	49.10
NOLVADEX	TAMOXIFENE	FILM-COATED TABLETS 10 MG	1 BOX 30 TABLETS	132.50	78.60	87.60	49.10
NOLVADEX	TAMOXIFENE	COATED TABLETS 20 MG	1 BOX 30 TABLETS	124.30	124.30	77.70	77.70
TAFEN	TAMOXIFENE	TABLETS 20 MG	1 BOX 30 TABLETS	124.30	124.30	77.70	77.70
TAMOXIFENE GT 20 MG	TAMOXIFENE	TABLETS 20 MG	1 BOX 30 TABLETS	124.30	124.30	77.70	77.70
TAMOXIFENE MYLAN	TAMOXIFENE	TABLETS 20 MG	1 BOX 30 TABLETS	124.30	124.30	77.70	77.70
UFT	TEGAFUR / URACILE	CAPSULE 100 / 224 MG / MG	1 BOX 21 CAPSULE	1,831.00	1,831.00	1,576.00	1,576.00
UFT	TEGAFUR / URACILE	CAPSULE 100 / 224 MG / MG	1 BOX 28 CAPSULE	2,442.00	2,442.00	2,102.00	2,102.00
UFT	TEGAFUR / URACILE	CAPSULE 100 / 224 MG / MG	1 BOX 35 CAPSULE	2,952.00	2,952.00	2,627.00	2,627.00
UFT	TEGAFUR / URACILE	CAPSULE 100 / 224 MG / MG	1 BOX 42 CAPSULE	3,463.00	3,463.00	3,153.00	3,153.00
TEMODAL	TEMOZOLOMIDE	CAPSULE 5 MG	1 BOTTLE 5 CAPSULE	219.00	219.00	137.00	137.00
TEMODAL	TEMOZOLOMIDE	CAPSULE 20 MG	1 BOTTLE 5 CAPSULE	840.00	840.00	558.00	558.00



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
TEMODAL	TEMOZOLOMIDE	CAPSULE 100 MG	1 BOTTLE 5 CAPSULE	3,156.00	3,156.00	2,837.00	2,837.00
TEMODAL	TEMOZOLOMIDE	CAPSULE 250 MG	1 BOTTLE 5 CAPSULE	6,392.00	6,392.00	6,168.00	6,168.00
THIOTEPA	THIOTEPA	POWDER FOR PARAENTERAL USE À 15 MG	1 BOX 1 BOTTLE	191.90	191.90	126.90	126.90
HERCEPTIN	TRASTUZUMAB	POWDER FOR PARAENTERAL USE À 150 MG	1 BOX 1 BOTTLE	6,890.00	6,890.00	6,681.00	6,681.00
DECAPEPTYL LP	TRIPTORELINE	POWDER FOR SUSPENSION INJECTION 3.75 MG	1 BOX 1 BOTTLE + AMPULE	1,456.00	1,456.00	1,190.00	1,190.00
DECAPEPTYL LP	TRIPTORELINE	POWDER FOR SOLUTION INJECTION 11.25 MG	1 BOX 1 BOTTLE + AMPULE	3,546.00	3,546.00	3,239.00	3,239.00
DECAPEPTYL	TRIPTORELINE	POWDER FOR SOLUTION INJECTION 0.1 MG	1 BOX 7 KIT	467.00	467.00	310.00	310.00
OKA-VINBLASTIN	VINBLASTINE	POWDER FOR SOLUTION INJECTION 10 MG	1 BOTTLE 10 ML	124.00	124.00	77.50	77.50
PHARMACRISTINE 1 MG/ML	VINCRISTINE	SOLUTION INJECTION 1 MG	1 BOX 1 BOTTLE	55.90	55.90	34.90	34.90
VINCRISTINE COOPER	VINCRISTINE	SOLUTION INJECTION 1 MG	1 BOX 1 BOTTLE	65.00	65.00	40.60	40.60
OKA-VINCRISTINE	VINCRISTINE	SOLUTION INJECTION 1 MG	1 BOX 1 BOTTLE	68.00	68.00	42.50	42.50
VINCRISTINE COOPER	VINCRISTINE	SOLUTION INJECTION 1 MG	1 BOX 5 BOTTLE	306.00	306.00	204.00	204.00
NAVELBINE	VINORELBINE	SOLUTION INJECTION 10 MG	1 BOTTLE 1 ML	246.00	246.00	154.00	154.00
NAVELBINE	VINORELBINE	SOLUTION INJECTION 10 MG	10 BOTTLE 1 ML	1,764.00	1,764.00	1,507.00	1,507.00
NAVELBINE	VINORELBINE	SOLUTION INJECTION 50 MG	1 BOTTLE 5 ML	1,022.00	1,022.00	743.00	743.00
NAVELBINE	VINORELBINE	SOLUTION INJECTION 50 MG	10 BOTTLE 5 ML	7,483.00	7,483.00	7,291.00	7,291.00
NAVELBINE	VINORELBINE	CAPSULES 20 MG	1 BOX 1 CAPSULE	771.00	771.00	512.00	512.00
NAVELBINE	VINORELBINE	CAPSULES 30 MG	1 BOX 1 CAPSULE	1,028.00	1,028.00	750.00	750.00
SOLUPRED	PREDNISOLONE		1 BOX 30 TABLETS	33.30	28.00	20.80	17.50
ISOLONE	PREDNISOLONE	TABLETS 20 MG	1 BOX 30 TABLETS	57.10	57.10	35.70	35.70
ORAPRED	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOX 30 TABLETS	65.00	65.00	40.60	40.60



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
ORAPRED 5 MG	PREDNISOLONE	EFFERVESCENT TABLETS 5 MG	1 BOX 60 TABLETS EFFERVESCENT	38.00	38.00	23.70	23.70
CORTANCYL	PREDNISONE	TABLETS 20 MG	1 BOX 20 TABLETS	45.80	45.80	28.60	28.60
ISONE	PREDNISONE	TABLETS 20 MG	1 BOX 20 TABLETS	57.10	57.10	35.70	35.70
ISONE	PREDNISONE	TABLETS 50 MG	1 BOX 20 TABLETS	85.80	85.80	53.60	53.60
ISONE	PREDNISONE	TABLETS 1 MG	1 BOX 30 TABLETS	12.30	12.30	7.70	7.70
CORTANCYL	PREDNISONE	TABLETS 1 MG	1 BOX 30 TABLETS	13.40	12.30	8.40	7.70
ISONE	PREDNISONE	TABLETS 5 MG	1 BOX 30 TABLETS	19.00	19.00	11.90	11.90
CORTANCYL	PREDNISONE	TABLETS 5 MG	1 BOX 30 TABLETS	22.80	19.00	14.20	11.90
CEKACORT	PREDNISONE / ACIDE ASCORBIQUE (VITAMINE C) / CHLORURE DE	GASTRO-RESISTANT COATED TABLETS 5 / 125 / 125 MG /	1 BOX 30 TABLETS	20.30	20.30	12.70	12.70
EFFIPRED	PREDNISOLONE	ORAL SOLUTION 1 MG	1 BOTTLE 50 ML	21.60	21.60	13.50	13.50
SOLUPRED	PREDNISOLONE	SOLUTION 1 MG	1 BOTTLE 50 ML	27.00	21.60	17.90	13.50
COTIPRED	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOX 20 TABLETS	48.50	48.50	30.30	30.30
PREDNISOLONE WIN	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOTTLE 20 TABLETS	35.50	35.50	22.20	22.20
HOSTACORTIN H	PREDNISOLONE	TABLETS 5 MG	1 BOX 20 TABLETS	21.70	21.70	13.60	13.60
SIPROZONE	PREDNISOLONE	TABLETS 20 MG	1 BOX 20 TABLETS	35.00	35.00	21.90	21.90
ISOLONE	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOX 20 TABLETS	40.00	40.00	25.00	25.00
PREDNI 20	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOX 20 TABLETS	42.00	42.00	26.20	26.20
EFFIPRED	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOX 20 TABLETS	58.40	58.40	36.50	36.50
SOLUPRED	PREDNISOLONE	EFFERVESCENT TABLETS 20 MG	1 BOX 20 TABLETS	58.40	58.40	36.50	36.50
ISOLONE	PREDNISOLONE	TABLETS 50 MG	1 BOX 20 TABLETS	85.80	85.80	53.60	53.60
ORAPRED 5 MG	PREDNISOLONE	EFFERVESCENT TABLETS 5 MG	1 BOX 30 TABLETS	20.00	20.00	12.50	12.50



Special or trade name	Common International name	Form of drug	Presentation	Public Price in Morocco (PPM)	Price base for reimbursement (PPM)	Price in Hospital Morocco (PHM)	Price for reimbursement (PHM)
ISOLONE	PREDNISOLONE	EFFERVESCENT TABLETS 5 MG	1 BOX 30 TABLETS	22.00	22.00	13.70	13.70
ISOLONE	PREDNISOLONE	EFFERVESCENT TABLETS 5 MG	1 BOX 30 TABLETS	23.00	23.00	14.40	14.40
EFFIPRED	PREDNISOLONE	EFFERVESCENT TABLETS 5 MG	1 BOX 30 TABLETS	28.00	28.00	17.50	17.50



6.5 Bibliography

1. *book, C.T.W.F. Morocco. [cited 2014 24th July]; Available from: <https://www.cia.gov/library/publications/the-world-factbook/fields/2102.html#138>.*
2. *Bank, W. Data: Morocco. 15th April, 2014]; Available from: <http://data.worldbank.org/country/morocco>.*
3. *Reports, U.H.D. Morocco. 15th April, 2014]; Available from: <http://hdr.undp.org/sites/default/files/Country-Profiles/MAR.pdf>.*
4. *Sante, R.d.M.M.d.l., strategie sectorielle de sante maroc 2012-2016. 2012.*
5. *Solidarity, E.F.f.D.a. Coutry update-Morocco. 2014 [cited 2014 15th December]; Available from: <http://www.europeanforum.net/country/morocco>.*
6. *WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]; Available from: http://www.who.int/workforcealliance/knowledge/PPE_Morocco_CaseStudy.pdf?ua=1.*
7. *WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]; Available from: http://www.who.int/countryfocus/cooperation_strategy/ccs_mar_en.pdf.*
8. *Observatory-WHO, R.H.S., Health System Profile-Morocco. 2006.*
9. *Ruger, J.P. and D. Kress, Health financing and insurance reform in Morocco. Health Aff (Millwood), 2007. 26(4): p. 1009-16.*
10. *CNSS, M. Key figures. 30th April, 2014]; Available from: <http://www.cnss.ma/fr/content/chiffres-cl%C3%A9s-1>.*
11. *ANAM, Roadmap 2014-18. 2014.*
12. *experts, D.w., Discussion with experts. 2014.*
13. *INTERNATIONALHEALTH, H.P.D.T.I.F. REGISTERING NEW DRUGS: THE AFRICAN CONTEXT. 6th April, 2014]; Available from: http://www.policycures.org/downloads/DNDi_Registering_New_Drugs-The_African_Context_20100108.pdf.*
14. *Dr Javier Guzman, Director of R., Health Policy Division, The George Institute for International Health. REGISTERING NEW DRUGS: THE AFRICAN CONTEXT New tools for new times. 6th April, 2014]; Available from: <http://www.conceptfoundation.org/files/meeting/16.%20Guzman%20-%20Registering%20new%20drugs%20the%20African%20context.pdf>.*
15. *Pharmaceutique, A.M.d.l.I. Loi n° 17-04 portant code du médicament et de la pharmacie. [cited 2014 18th July]; Available from: http://www.amip.ma/dynamicdata/Secteur_Codepharmacie.aspx.*



6.6 Methodology

6.6.1 Secondary research

In-depth and extensive secondary research was conducted to capture quantitative and qualitative information by a team of experienced consultants with advanced analytical skills and expertise in the pharmaceutical industry. The data was collected from multiple credible and authentic sources within public domain, including but not limited to:

- Websites of Ministry of Health and its affiliates as well as various regulatory and government bodies.
- Company websites, annual reports, investor presentations and press releases of various pharmaceutical companies and hospitals.
- Reports of various healthcare and pharmaceutical trade associations.
- Reports published by various internationally recognized bodies such as World Health Organization (WHO), United Nations (UN), and others.
- Reports and articles published by globally accredited institutions such as the World Bank, International Monetary Fund (IMF), Asian Development Bank (ADB), the Organization for Economic Cooperation and Development (OECD), Central Banks of respective countries and many more.
- News, press releases and bulletins of domestic as well as foreign newspapers and magazines.
- Publications in various scientific, healthcare and other related journals.

6.6.2 Data validation

Both the primary and secondary data was validated by a panel of experts including industry experts, KOLs, thought leaders and members of phamax Dendron Network.

6.7 Disclaimer

All information contained in this publication has been thoroughly researched and compiled from various sources that are believed to be accurate and credible at the time of publishing. However, in view of the natural scope for human and/or mechanical error, either at source or during production, phamax accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions from any part of the publication. All information is provided without warranty, and phamax makes no representation of warranty of any kind as to the accuracy or completeness of any information hereto contained.

The information contained in this report is strictly confidential and has been provided to the client under a non-exclusive and non-transferable license for the client's direct benefit and use only. The report should not be copied, electronically transmitted, sold or divulged to any other party without the prior written consent of phamax.

© 2015 phamax AG. All rights reserved.



6.8 Contact us

All communications pertaining to this report should be addressed to:

SWITZERLAND OFFICE

phamax AG
Passage 6,
4104 Oberwil (BL), SWITZERLAND
Phone: +41 61821 5687
Fax: +41 61821 5836
E-mail: info@phamax.ch

INDIA OFFICE

phamax Analytic Resources Pvt. Ltd.
#19, "KMJ Ascend", 1st Cross, 17th C Main,
5th Block, Koramangala,
Bangalore 560 095, INDIA
Phone no: +91 80 6745 1100
Fax no: +91 80 6745 1122
E-mail: info@phamax.ch